

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07C 217/58, 255/37, 235/34, A61P 25/24, 25/28, A61K 31/135	A1	(11) International Publication Number: WO 00/50380 (43) International Publication Date: 31 August 2000 (31.08.00)
--	----	---

(21) International Application Number: PCT/IB00/00108 (22) International Filing Date: 2 February 2000 (02.02.00) (30) Priority Data: 60/121,313 23 February 1999 (23.02.99) US (71) Applicant (<i>for all designated States except US</i>): PFIZER PRODUCTS INC. [US/US]; Eastem Point Road, Groton, CT 06340 (US). (72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): ELLIOTT, Mark, Leonard [US/US]; 58 Baldwin Brook Road, Canterbury, CT 06331 (US). HOWARD, Harry, Ralph, Jr. [US/US]; 272 Westwoods Terrace, Bristol, CT 06010 (US). SCHMIDT, Christopher, Joseph [US/US]; 11 Maywood Drive, Old Lyme, CT 06371 (US). SEEGER, Thomas, Francis [US/US]; 77 Oakwood Road, Mystic, CT 06355 (US). (74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
--	--

(54) Title: MONOAMINE REUPTAKE INHIBITORS FOR TREATMENT OF CNS DISORDERS

(57) Abstract

The present invention relates to compounds that are a useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

MONOAMINE REUPTAKE INHIBITORS FOR
TREATMENT OF CNS DISORDERS

Background of the Invention

Serotonin Selective Reuptake Inhibitors (SSRIs) currently provide efficacy in the treatment of major depressive disorder (MDD) and are generally perceived by psychiatrists and primary care physicians as effective, well-tolerated and easily administered. However, they are associated with undesirable features, such as high incidence of sexual dysfunction, delayed onset of action and a level of non-responsiveness estimated to be as high as 30% (see M. J. Gitlin, Journal of Clinical Psychiatry, 1994, 55, 406-413 and R. T. Segraves, Journal of Clinical Psychiatry, 1992, 10(2), 4-10). Preclinical and clinical evidence has indicated that the sexual dysfunction associated with SSRI therapy can be reduced through the use of dopamine reuptake inhibitors (DRIs), such as bupropion (see A. K. Ashton, Journal of Clinical Psychiatry, 1998, 59(3), 112-115). Furthermore, the combination of SRI and DRI may hasten the onset of action as well as offering relief to refractory patients, possibly through a synergistic mechanism (see R. D. Marshall et al, Journal of Psychopharmacology, 1995, 9(3), 284-286).

This invention relates to novel biaryl ether derivatives that exhibit activity as monoamine (e.g., dopamine, serotonin) reuptake inhibitors, to pharmaceutical compositions containing such compounds and to methods of using such compounds to treat central nervous system (CNS) and other disorders.

United States Patent 4,018,830, published on April 19, 1997, refers to phenylthioaralkylamines and 2-phenylthiobenzylamines which are active as antiarrhythmics.


PCT publication 97/17325, published on May 15, 1997, refers to derivatives of N,N-dimethyl-2-(arylthio)benzylamine which selectively influence serotonin transport in the central nervous system and are useful as antidepressants.

United States Patent 5,190,965, published on March 2, 1993, and United States Patent 5,430,063, issued July 4, 1995, refer to phenoxyphenyl derivatives which have utility in the treatment of depression.

United States Patent 4,161,529, published on July 17, 1979, refers to pyrrolidine derivative which possess anticholesteremic and hypolipemic activity.

Summary of the Invention

The present invention relates to compounds of the formula



wherein phenyl ring A and phenyl ring B can each, independently, be replaced by a naphthyl group, and wherein when phenyl ring A is replaced by a naphthyl group, the ethereal oxygen of structure I and the carbon to which R³, R⁴ and NR¹R² are attached, are attached to adjacent ring carbon atoms of the naphthyl group and neither of said adjacent ring carbon atoms is also adjacent to a fused ring carbon atom of said naphthyl group;

- 5 n and m are, selected, independently, from one, two and three;

10 R¹ and R² are selected, independently, from hydrogen, (C₁-C₄)alkyl, (C₂-C₄)alkenyl, and (C₂-C₄)alkynyl, or R¹ and R², together with the nitrogen to which they are attached, form a
15 four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R¹ and R² are attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, with the proviso that said ring can not contain two adjacent oxygen atoms or two adjacent sulfur atoms, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C₁-C₆)alkyl;

20 R³ and R⁴ are selected, independently, from hydrogen and (C₁-C₄) alkyl optionally substituted with from one to three fluorine atoms, or R³ and R⁴, together with the carbon to which they are attached, form a four to eight membered saturated carbocyclic ring, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C₁-C₆)alkyl;

25 or R² and R³, together with the nitrogen to which R² is attached and the carbon to which R³ is attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R² is attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, with the proviso that said ring can not contain two adjacent oxygen atoms or two adjacent sulfur atoms, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C₁-C₆)alkyl;

each X is selected, independently, from hydrogen, halo (*i.e.*, chloro, fluoro, bromo or iodo), (C₁-C₄)alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₄)alkoxy

optionally substituted with from one to three fluorine atoms, cyano, nitro, amino, (C₁-C₄)alkylamino, di-[(C₁-C₄)alkyl]amino, NR⁵(C=O)(C₁-C₄)alkyl, SO₂NR⁵R⁶ and SO_p(C₁-C₆)alkyl, wherein R⁵ and R⁶ are selected, independently, from hydrogen and (C₁-C₆)alkyl, and p is zero, one or two; and

- 5 each Y is selected, independently, from hydrogen, (C₁-C₆)alkyl and halo;
with the proviso that: (a) no more than one of NR¹R², CR³R⁴ and R²NCR³ can form a ring; and (b) at least one X must be other than hydrogen when (i) R³ and R⁴ are both hydrogen, (ii) R¹ and R² are selected, independently, from hydrogen and (C₁-C₄)alkyl, and (iii) ring B is mono- or disubstituted with, respectively, one or two halo groups;
- 10 and the pharmaceutically acceptable salts thereof.

The present invention also relates to a pharmaceutical composition for treating a disorder or condition selected from hypertension, depression (e.g., depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, 15 major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, cocaine, heroin, 20 phenobarbital, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral 25 vasculature), cerebellar ataxia, gastrointestinal tract disorders (involving changes in motility and secretion), negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder (ADHD), chronic paroxysmal hemicrania and headache (associated with vascular disorders) in a mammal, preferably a human, 30 comprising an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating such disorder or condition and a pharmaceutically acceptable carrier.

The present invention also relates to a pharmaceutical composition for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, dopamine or 35 norepinephrine in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such

disorder or condition and a pharmaceutically acceptable carrier. Examples of such disorders and conditions are those enumerated in the preceding paragraph.

- The present invention also relates to a method for treating a disorder or condition selected from hypertension, depression (e.g., depression in cancer patients, depression in 5 Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, premature 10 ejaculation, eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in 15 Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders (involving changes in motility and secretion), negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention 20 deficit hyperactivity disorder (ADHD), chronic paroxysmal hemicrania and headache (associated with vascular disorders) in a mammal, preferably a human, comprising administering to a mammal in need of such treatment an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition.
- 25 The present invention also relates to a method for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, preferably a human, comprising administering to a mammal in need of such treatment an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition.
- 30 The present invention also relates to a pharmaceutical composition for treating a disorder or condition selected from hypertension, depression (e.g., depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant 35

personality disorder, premature ejaculation, eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders (involving changes in motility and secretion), negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder (ADHD), chronic paroxysmal hemicrania and headache (associated with vascular disorders) in a mammal, preferably a human, comprising a serotonin, dopamine or norepinephrine reuptake inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present invention also relates to a pharmaceutical composition for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, norepinephrine or dopamine in a mammal, preferably a human, comprising serotonin, dopamine or norepinephrine reuptake inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present invention also relates to a method for treating a disorder or condition selected from hypertension, depression (e.g., depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, sexual dysfunction (e.g., premature ejaculation), eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders (involving changes in motility

and secretion), negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder (ADHD), chronic paroxysmal hemicrania and headache (associated with vascular disorders) in a mammal, preferably a human,

5 comprising administering to a mammal requiring such treatment a serotonin, dopamine or norepinephrine reuptake inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.

The present invention also relates to a method for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, norepinephrine or dopamine in a mammal, preferably a human, comprising administering to a mammal requiring such treatment a serotonin, dopamine or norepinephrine reuptake inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.

The present invention relates to a pharmaceutical composition for treating a condition or disorder that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, preferably a human, comprising:

- a) a pharmaceutically acceptable carrier;
- b) a compound of the formula I or a pharmaceutically acceptable salt thereof; and
- c) an NK-1 receptor antagonist or a 5HT_{1D} receptor antagonist, or a pharmaceutically acceptable salt thereof;

wherein the amount of the active compounds (*i.e.*, the compound of formula I and the NK-1 receptor antagonist or 5HT_{1D} receptor antagonist) are such that the combination is effective in treating such disorder or condition.

The present invention also relates to a method for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, preferably a human, comprising administering to a mammal requiring such treatment:

- a) a compound of the formula I, defined above, or a pharmaceutically acceptable salt thereof; and
- b) an NK-1 receptor antagonist or a 5HT_{1D} receptor antagonist, or a pharmaceutically acceptable salt thereof;

wherein the amounts of the active compounds (*i.e.*, the compound of formula I and the NK-1 receptor antagonist or 5HT_{1D} receptor antagonist) are such that the combination is effective in treating such disorder or condition.

35 This invention also relates to the pharmaceutically acceptable acid addition salts of the compounds of formula I. Examples of pharmaceutically acceptable acid addition salts of

the compounds of formula I are the salts of hydrochloric acid, p-toluenesulfonic acid, fumaric acid, citric acid, succinic acid, salicylic acid, oxalic acid, hydrobromic acid, phosphoric acid, methanesulfonic acid, tartaric acid, maleic acid, di-p-toluoyl tartaric acid, acetic acid, sulfuric acid, hydroiodic acid and mandelic acid.

5 Unless otherwise indicated, the term "halo", as used herein, includes fluoro, chloro, bromo and iodo.

Unless otherwise indicated, the term "alkyl", as used herein, may be straight, branched or cyclic, and may include straight and cyclic moieties as well as branched and cyclic moieties.

10 The term "treatment", as used herein, refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such condition or disorder. The term "treatment", as used herein, refers to the act of treating, as "treating" is defined immediately above.

15 The compounds of formula I may have optical centers and therefore may occur in different enantiomeric configurations. The invention includes all enantiomers, diastereomers, and other stereoisomers of such compounds of formula I, as well as racemic and other mixtures thereof.

20 The present invention also relates to all radiolabelled forms of the compounds of the formula I. Preferred radiolabelled compounds of formula I are those wherein the radiolabels are selected from as ^3H , ^{11}C , ^{14}C , ^{18}F , ^{123}I and ^{125}I . Such radiolabelled compounds are useful as research and diagnostic tools in metabolism pharmacokinetics studies and in binding assays in both animals and man.

25 "Chemical dependency," as used herein, means an abnormal craving or desire for, or an addiction to a drug. Such drugs are generally administered to the affected individual by any of a variety of means of administration, including oral, parenteral, nasal or by inhalation. Examples of chemical dependencies treatable by the methods of the present invention are dependencies on alcohol, nicotine, cocaine, heroin, phenobarbital, and benzodiazepines (e.g., Valium (trademark)). "Treating a chemical dependency," as used herein, means reducing or alleviating such dependency.

30 Preferred embodiments of this invention include the following compounds of the formula I and their pharmaceutically acceptable salts:

[2-(3,4-Dichlorophenoxy)-5-fluorobenzyl]-dimethylamine;

[2-(3,4-Dichlorophenoxy)-5-fluorobenzyl]-methylamine;

[2-(3,4-Dichlorophenoxy)-5-trifluoromethylbenzyl]-dimethylamine;


35 N-[4-(3,4-Dichlorophenoxy)-3-dimethylaminomethylphenyl]-acetamide;

{1-[2-(3,4-Dichlorophenoxy)phenyl]-ethyl}-dimethylamine;

- [2-(3,4-Dichlorophenoxy)-4-trifluoromethylbenzyl]-dimethylamine;
[2-(3,4-Dichlorophenoxy)-4-trifluoromethylbenzyl]-methylamine;
[4-Chloro-2-(3,4-dichlorophenoxy)-benzyl]-methylamine;
{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine;
5 {1-[2-(3,4-Dichlorophenoxy)phenyl]-ethyl}-methylamine;
{1-[2-(4-Chlorophenoxy)phenyl]ethyl}-methylamine;
[2-(3,4-Dichlorophenoxy)-5-methoxybenzyl]-methylamine;
[2-(4-Chlorophenoxy)-5-fluorobenzyl]-methylamine; and
{1-[2-(4-Chlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine.
- 10 [2-(3,4-Dichlorophenoxy)-5-methylbenzyl]-dimethylamine;
[4-Bromo-2-(3,4-dichlorophenoxy)-benzyl]-methylamine;
[5-Bromo-2-(3,4-dichlorophenoxy)-benzyl]-methylamine;
[2-(3,4-Dichlorophenoxy)-4,5-dimethoxybenzyl]-methylamine;
[2-(3,4-Dichlorophenoxy)-4-methoxybenzyl]-dimethylamine;
- 15 4-(3,4-Dichlorophenoxy)-3-methylaminomethyl-benzonitrile;
[2-(3,4-Dichlorophenoxy)-4,5-dimethylbenzyl]-methylamine;
3-(3,4-Dichlorophenoxy)-4-methylaminomethyl-benzonitrile;
(+)-{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine;
(-)-{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine;
- 20 [2-(3,4-Dichlorophenoxy)-5-trifluoromethyl-benzyl]-methylamine;
[2-(3,4-Dichlorophenoxy)-4-methoxybenzyl]-methylamine;
[2-(4-Chloro-3-fluorophenoxy)-5-fluorobenzyl]-methylamine;
[2-(3-Chloro-4-fluorophenoxy)-5-fluorobenzyl]-methylamine;
(+/-)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine;
- 25 (-)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine;
(+)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine; and
2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-N-methylpyrrolidine.
- Other embodiments of this invention include the following compounds and their pharmaceutically acceptable salts:
- 30 {1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1-methylethyl}-methylamine;
{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1-methylethyl}-dimethylamine;
[4-Chloro-2-(4-chlorophenoxy)-5-fluorobenzyl]-methylamine;
[2-(3,4-Dichlorophenoxy)-5-fluoro-4-methoxybenzyl]-methylamine;
[4-(3,4-Dichlorophenoxy)-3-(dimethylaminomethyl)-phenyl]-dimethylamine
- 35 [5-Fluoro-2-(4-fluoro-3-methoxyphenoxy)-benzyl]-dimethylamine;
[2-(4-Chlorophenoxy)-5-isopropylbenzyl]-methylamine;

- {1-[2-(4-Chlorophenoxy)-5-trifluoromethylphenyl]-ethyl}-methylamine;
[2-(4-Chlorophenoxy)-4,5-dimethylbenzyl]-methylamine;
{1-[5-Chloro-2(3,4-dichlorophenoxy)phenyl]-propyl}-methylamine;
[2-(3,4-Dichlorophenoxy)-5-methylsulfanyl-benzyl]-methylamine;
5 {1-[2-(3,4-Dichlorophenoxy)-5-methylsulfanyl-phenyl]-ethyl}-methylamine;
{1-[2-(3,4-Dichlorophenoxy)-5-methylsulfanyl-phenyl]-1-methylethyl}-methylamine;
[2-(3,4-Dichlorophenoxy)-5-methylsulfanyl-benzyl]-dimethylamine;
[2-(3,4-Dichlorophenoxy)-5-methanesulfinyl-benzyl]-dimethylamine ;
[2-(3,4-Dichlorophenoxy)-5-methanesulfinyl-benzyl]-methylamine;
10 [2-(3,4-Dichlorophenoxy)-5-methanesulfonyl-benzyl]-methylamine;
[2-(3,4-Dichlorophenoxy)-5-methanesulfonyl-benzyl]-dimethylamine;
[2-(3,4-Dichlorophenoxy)-5-(propane-2-sulfonyl)-benzyl]-methylamine;
2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-piperidine;
2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1-methyl-piperidine;
15 3-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-4-methyl-morpholine;
2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1,2-dimethyl-piperidine;
{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-cyclopropyl}-dimethylamine;
2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1,5-dimethyl-pyrrolidine;
3-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-4-methyl-thiomorpholine;
20 {1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-cyclopentyl}-methylamine;
{1-[2-(3,4-Dichlorophenoxy)-5-(propane-2-sulfonyl)-phenyl]-ethyl}-methylamine; and
[4-Chloro-2-(3,4-dichlorophenoxy)-5-methanesulfonyl-benzyl]-methylamine.
Other embodiments of this invention relate to the compound of the formula I wherein
m is zero, n is one, R³ and R⁴ are hydrogen, X is chloro, bromo, iodo or methyl, R¹ is hydrogen
25 and R² is methyl.

This invention also relates to compounds of the formula




wherein Q is -C(=O)H, cyano, -C(=O)OH or -C(=O)NR¹R² wherein R¹ and R² are selected, independently, from hydrogen and (C₁-C₄)alkyl, or R¹ and R², together with the

nitrogen to which they are attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R¹ and R² are attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, with the proviso that said ring can not contain two adjacent oxygen atoms or two adjacent sulfur atoms, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C₁-C₆)alkyl.

5 These compounds are useful as intermediates in the synthesis of certain compounds of the formula I.

This invention also relates to compounds having the formula




10


and the pharmaceutically acceptable salts thereof. These compounds and their pharmaceutically acceptable salts also exhibit activity as monoamine reuptake inhibitors and are useful for treating the disorders and conditions referred to above.


The compounds of formula XVIII may have optical centers and therefore may occur in
15 different enantiomeric configurations. The invention includes all enantiomers, diastereomers, and other stereoisomers of such compounds of formula XVIII, as well as racemic and other mixtures thereof.


Detailed Description of the Invention


Compounds of the formula I may be prepared according to the following reaction
20 Schemes and discussion. Unless otherwise indicated, A, B, R¹, R², R³, R⁴, R⁵, R⁶, X, Y, m and n, and structural formulas I and XVIII, in the reaction schemes and discussion that follows are as defined above.

SCHEME 1

SCHEME 2

SCHEME 3

SCHEME 4


SCHEME 5

XII

IV

SCHEME 6


5




XIII

XIV

IV

SCHEME 7

Scheme 1 refers to the preparation of compounds of the formula I from compounds of the formulas II and III. Compounds of the formulas II and III are commercially available or can be made by methods well known to those of ordinary skill in the art. For example, compounds of general formulas IIa and IIb wherein R³ is H may be prepared by introducing an aldehyde functional group (CHO) to a compound of formula XV or XVI, respectively, using methods well known to those of skill in the art.




When L = F, the procedure of A. J. Bridges *et al.*, Tetrahedron Letters, **1992**, 33(49), 7499-7502, is particularly useful for the synthesis of substituted ortho-fluorobenzaldehydes. Other 10 such transformations have been described by C. F. H. Allen *et al.*, Organic Synthesis, **1951**, 31, 92; T. DePaulis *et al.*, J. Med. Chem., **1986**, 29, 61; I. M. Godfrey *et al.*, J. Chemical Society, Perkin Transactions 1, **1974**, 1353; K. M. Tramposil *et al.*, J. Med. Chem., **1983**, 26(2), 121; and M. E. Cracknell *et al.*, Chem. Ind., (London), **1985**, (9), 309.

Referring to Scheme 1, a compound (*i.e.*, an aldehyde or ketone) of the formula IIa, 15 wherein L is a suitable leaving group such as fluoro, chloro, nitro or triflate, is reacted with a compound (*i.e.*, a phenol) of the formula IIIa in the presence of a base to form the corresponding compound of formula IV. This reaction is generally carried out at a temperature from about 0°C to about 150°C for about 1 hour to about 3 days, preferably at about 90-95°C for about 18 hours, in a polar solvent such as dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA) or N-methyl-2-pyrrolidinone (NMP), 20 preferably DMF. Suitable bases include anhydrous sodium carbonate (Na₂CO₃), potassium carbonate (K₂CO₃), sodium hydroxide (NaOH), potassium hydroxide (KOH) and amines such as pyrrolidine, triethylamine and pyridine, with anhydrous K₂CO₃ being preferred. Details for conducting this procedure can be found in G. W. Yeager *et al.*, Synthesis, **1995**, 28-30; J. R. 25 Dimmock *et al.*, Journal of Medicinal Chemistry, **1996**, 39(20), 3984-3997. Alternatively, phenols of the formula IIb and compounds of the formula IIIb may be converted into aldehydes or ketones of the general formulae IV according to the procedures described by K. Tomisawa *et al.*, Chemical and Pharmaceutical Bulletin, **1984**, 32(8), 3066-3074.

Compounds of the formula IV can be converted into compounds of the formula I by 30 subjecting them to reductive amination conditions. For example, a compound of the formula

IV can be reacted with a compound of the formula HNR^1R^2 to form an intermediate of the formula **XVII**:



XVII

- 5 which may be isolated or converted directly in the same reaction step into a compound of the formula **I**. This conversion, whether in situ or starting with the isolated compound of formula **XVII**, can be performed using one or more methods known to those skilled in the art.

For example, the compound of formula **IV** and the appropriate compound of formula HNR^1R^2 can be combined in the presence of a dehydrating reagent such as titanium (IV) 10 tetrachloride or titanium (IV) isopropoxide, in a reaction inert solvent such as benzene, toluene, ethanol or a like solvent, until the reaction is judged to be complete, according to the procedure of S. Bhattacharyya (*Journal of Organic Chemistry*, 1995, 60(15), 4928-4929). Alternatively, the compound of formula **IV** and the compound of formula HNR^1R^2 can be combined in an inert solvent such as benzene or toluene, in the presence or absence of a 15 water scavenger such as molecular sieves, and heated to eliminate water generated during the formation of the intermediate of formula **XVII**. The degree of completion of the conversion of compounds of the formula **IV** into the above intermediate(s) of formula **XVII** can be assessed using one or more known analytical techniques, including $^1\text{H-NMR}$ spectroscopy.

In some instances, it may be possible or desirable to isolate the intermediate(s) of 20 formula **XVII**, or they may be further reacted with a reducing agent selective for the reduction of the intermediate to the desired compounds of formula **I**. Such reducing agents are widely known to those skilled in the art and include, for example, sodium borohydride (NaBH_4), sodium cyanoborohydride (NaBH_3CN) and sodium triacetoxy-borohydride (NaBH(OAc)_3), as described by A. F. Abdel-Magid *et al.* in *Tetrahedron Letters*, 1990, 31, 5595). This reduction 25 is generally carried out in a polar solvent such as methanol, ethanol, isopropanol or a like

solvent, and at temperatures of about 0°C to about 100°C, preferably at room temperature. In the procedure described by Bhattacharyya, the intermediate of formula **XVII** is formed in an ethanol solvent and, without isolation, is reduced to the product of formula **I** using NaBH₄. As an alternative to the aldehyde or ketone intermediates of formula **IV**, one skilled in the art can
5 also prepare compounds of formula **VI** (i.e., nitriles), as illustrated in Scheme 2, for use as intermediates in the syntheses of the desired compounds of formula **I**, using a diphenyl ether formation procedure analogous to that described in Scheme 1. Procedures for preparation of compounds of formula **VI** can be adapted from those found in the literature. (See, e.g., D. C.
10 Remy et al., *J. Med. Chem.*, 1975, 18(2), 142-148; E. A. Schmittling et al., *Journal of Organic Chemistry*, 1993, 58(12), 3229-3230).

The conversion of the nitriles of formula **VI** so obtained into the desired products of formula **I** can be achieved by several routes, as depicted in Scheme 2. For example, the nitrile group of **VI** can be hydrolyzed under acidic conditions using methods well known to those of skill in the art, to produce a carboxylic acid derivative of formula **VII**. (See, e.g., A. I.
15 Meyers et al., *Tetrahedron Letters*, 1984, 25 (28), 2941; and R. W. Higgins et al., *J. Organic Chemistry*, 1951, 16, 1275). This carboxylic acid derivative, in turn, can be converted into a carboxamide derivative having the formula **VIII** using one or more standard methods which are disclosed in the chemical literature, e.g., via reaction of an acid halide prepared from compounds of the formula **VII** with an amine of general formula HNR¹R². (See R. E. Kent et
20 al., *Organic Synthesis*, Coll. Vol. III, 1955, 490; and R. M. Herbst et al., *Organic Synthesis*, Coll. Vol. II, 1943, 11 for discussions of the Schotten-Bauman reaction). The resulting carboxamides of the formula **VIII**, wherein R¹ and R² are hydrogen, can also be prepared directly from the corresponding nitriles of formula **VI** by specific hydrolysis methods, employing, for example, hydrogen peroxide or strong aqueous alkalis metal salts. (See
25 *Chemistry & Industry*, 1961, 1987; C. R. Noller, *Organic Synthesis*, Coll. Vol. II, 1943, 586; and J. H. Hall and M. Gisler, *J. Organic Chemistry*, 1976, 41, 3769). Subsequently, the carboxamide derivatives of formula **VIII** may be reduced using one of a variety of reducing agents available for such conversion, to produce the desired compounds of formula **I**. (See,
e.g., A. C. Cope et al., *Organic Synthesis*, Coll. Vol. IV, 1963, 339, for use of lithium aluminum
30 hydride in a diethyl ether or THF solvent.) Alternatively, the nitriles of formula **VI** can be reduced to form the desired compounds of general formula **I**, wherein R¹ and R² are hydrogen, by using one of a variety of reducing agents disclosed in the chemical literature which are selective for this transformation (including catalytic hydrogenation using hydrogen gas and platinum (II) oxide, as described by J. A. Secrist, III and M. W. Logue in *J. Organic Chemistry*,
35 1972, 37, 335; hydrazine hydrate and Raney nickel in ethanol, as described by W. W. Zajac, Jr. et al. in *J. Organic Chemistry*, 1971, 36, 3539; and sodium trifluoroacetoxy borohydride in

THF, as described by N. Umino *et al.* in Tetrahedron Letters, 1976, 2875). Such reducing agents can also include lithium aluminum hydride in a nonreactive solvent such as diethyl ether or tetrahydrofuran.

Finally, the nitriles of formula VI may be converted to the corresponding aldehydes of general formula IV, wherein R³ is hydrogen, using reaction conditions specific for this transformation, such as lithium triethoxyaluminum hydride in a solvent such as THF or diethyl ether, as described by H. C. Brown and C. P. Garg in J. American Chemical Society, 1964, 86, 1085 and by J. Malek and M. Cerny in Synthesis, 1972, 217.

Using an alternative synthetic pathway, the intermediate carboxylic acids of formula VII (or their methyl or ethyl ester derivatives) can be reduced to their corresponding benzylic alcohols of formula IX. This process is well preceded in the literature and can be accomplished using selective reducing agents such as sodium borohydride (see, *e.g.*, J. V. B. Kanth *et al.*, J. Organic Chemistry, 1991, 56, 5964), diborane in THF (see, *e.g.*, M. N. Moon *et al.*, J. Organic Chemistry, 1973, 38, 2786), and similar reducing agents.

The alcohols of formula IX so obtained can then be selectively re-oxidized to form the corresponding aldehydes of formula IV (R³ = H), for example, using pyridinium chlorochromate in methylene chloride, according to the procedure of E. J. Corey *et al.*, Tetrahedron Letters, 1975, 31, 2647-2650, or C.-G. Huang, Journal of Organic Chemistry, 1991, 56(16), 4846-4853. The hydroxyl group of the compound of formula IX may be also converted into a more reactive leaving group L² (*e.g.*, mesylate, triflate), as described in the scientific literature (see, *e.g.*, M. S. Newman *et al.*, J. Organic Chemistry, 1974, 39, 1036; and E. K. Anderson *et al.*, Synthesis, 1974, 665), to generate intermediates of the formula X, which can then be reacted with the appropriate amines of formula HNR¹R² to produce the corresponding desired compounds of formula I.

Schemes 3 and 4 illustrate processes that can be used to introduce substituents (R³, R⁴) at the alpha position of the benzylamine side chain. In Scheme 3, according to the procedure of D.J. Calderwood *et al.*, (Tetrahedron Letters, 1997, 38(7), 1241-1244), a nitrile of the formula VI or an amide of the formula VIII can be treated with a reagent of the formula R³MJ₂ (wherein M is a metal such as cerium and J is a halogen such a Cl or Br) to produce a compound of the formula I wherein R¹=R²=hydrogen. Such compounds can then be converted to compounds of formula I wherein R¹ and R² are other than hydrogen, for example, via the reductive amination procedures described herein.

Alternatively, according to Scheme 4, intermediates of the formula IV can be reacted with, for example, a Grignard reagent (*i.e.*, R⁴MgJ) under well established conditions to generate the intermediate alcohols of formula XI. Such alcohols of formula XI may be converted in one of several manners. For example, the alcohol may be reacted with NaN₃ in

- aqueous DMF, replacing the OH in formula **XI** with N₃, according to the procedure of Sharpless *et al.*, Tetrahedron Letters, **1996**, 37(19), 3219-3222. The azide derivative thus formed can then be reduced to the primary amine of formula **I** (R¹=R²=H) under a variety of conditions, for example, using hydrogen and barium sulfate in ethanol, (A. Guy *et al.*, **5** Synthesis, **1988**, 11, 900-904), lithium aluminum hydride in ether (M. Saito *et al.*, Journal of Medicinal Chemistry, **1980**, 23(12), 1364) or tributyltin hydride in benzene (J. Wasserman *et al.*, Journal of American Chemical Society, **1985**, 107(2), 519). The primary amine (-NH₂) compound of formula **I** so obtained can be converted to compounds of formula **I** wherein R¹ and R² are other than hydrogen, as described previously.
- 10 In addition to the methods described above in Schemes 1 and 2 for the preparation of the intermediate aldehydes and ketones of formula **IV**, other methods exist which can provide compounds of the formula **IV**. For example, a compound of formula **XII**, in which the group Z is a hydrogen atom, can be reacted, under conditions of Friedel-Crafts acylation (e.g., AlCl₃/CH₂Cl₂/R³COCl), to produce ketones of the formula **IV** in which R³ is not hydrogen. This **15** procedure is depicted in Scheme 5 and is well preceded in the scientific literature and familiar to those skilled in the art. The location of the acyl group (COR³) can be determined by the nature and location of the X and/or Y substituents present, as well as the conditions employed for the reaction. In instances where it is desireable to prepare compounds of formula **IV** (R³ = H), from **XII** (Z=H), introduction of the aldehyde functional group (CHO) may **20** be achieved using conditions described above for the preparation of the intermediates IIa and IIb in Scheme 1.

Preparation of compounds of the formula **IV** wherein R₃ = H (i.e., aldehydes) can be achieved using one or more of the known procedures for the formylation of aromatic rings, including reacting dichloromethyl methyl ether and titanium (IV) tetrachloride in methylene **25** chloride according to the procedure described by M. L. Mancini *et al.*, Synthetic Communications, **1989**, 2001-2007, or H. Chikashita *et al.*, J. Organic Chemistry, **1991**, 56, 1692.

Alternatively, reaction of the compounds of formula **XII** wherein Z is a halogen (e.g., Br, I) with a strong base (e.g., n-sec- or tert-butyl lithium, lithium diisopropylamide) in an inert **30** solvent such as hexane or THF, followed by reaction with a reagent such as N,N-dimethylformamide (DMF), will produce aldehydes like those of formula **IV**. (See G. Voss *et al.*, Chemische Berichte, **1989**, 122, 1199; M. P. Hoyer *et al.*, J. Organic Chemistry, **1986**, 51(26), 5106; and N. Eisen *et al.*, Angew. Chem. International Edition, **1986**, 25(11), 1026).


Another method for the preparation of compounds of formula **IV** relies on the oxidation **35** of an alkyl group (e.g., CH₃, C₂H₅) at the Z position of compounds of the formula **XII**. The oxidation can progress to the formation of the aldehyde of the formula **IV**, wherein R³ = H

(e.g., F. M. Hauser *et al.*, *Synthesis*, 1987, 723; S. D. Carter *et al.*, *Synthesis*, 1983, (12), 1000; European Patent 451650, 1991, Bayer AG), or, under more vigorous conditions, can proceed to the formation of a carboxylic acid compound of formula **VII**, from which it can then be converted into compounds of the formula **I**, as depicted in Scheme 2. The success of this
5 oxidation procedure will, of course, depend upon the nature and location of any additional substituents X and Y on the compounds of formula **XII**.

Yet another alternative for the preparation of the intermediates of formula **IV** is illustrated by Scheme 6. Compounds of the formula **XIII**, containing a nitro group and prepared according to procedures described by R. Beugelmans *et al.* (*Tetrahedron Letters*,
10 1994, 35(31), 5649-5652), J. H. Clark *et al.*, (*Tetrahedron Letters*, 1987, 28(31), 3627) and E. Roberts *et al.*, (*Journal of the Chemical Society*, 1925, 127, 2004), can be reduced under conditions disclosed in the chemical literature to the corresponding amine compounds of formula **XIV**. These reductions can be accomplished using gaseous hydrogen (H_2) and a catalyst (e.g., Pd/C, Raney nickel) in an alcohol solvent such as ethanol, at pressures of about
15 one to about 5 atmospheres of H_2 , or using an *in situ* reduction using an iron/acetic acid or tin/hydrochloric acid system to produce the corresponding compounds of formula **XIV**. These latter intermediates of formula **XIV** can then be converted, via their diazonium salts (prepared, for example, using $NaNO_2$ and aqueous HCl) into the nitriles of formula **VI** (i.e., see H. T. Clarke and R. R. Read, *Organic Synthesis*, 1941, 514) which may then be converted via the
20 corresponding carboxylic acids of formula **VII** as shown in Scheme 2 into aldehydes of the general formula **IV** wherein $R^3 = H$.

The intermediates of formula **XIV** can also be converted directly into the corresponding aldehydes of formula **IV** by reacting them with formaldoxime, followed by acid hydrolysis, as described by R.B. Woodward *et al.*, *Tetrahedron*, 1958, 2, 1 and W. F. Beech in
25 *J. Chemical Society*, 1954, 1297.

For the preparation of compounds of the general formula **I** wherein R^2 and R^3 taken together with the nitrogen to which R^2 is attached and the carbon to which R^3 is attached form a nitrogen containing ring, an adaptation of the procedure described by L. S. Bleicher *et al* (*J. Organic Chemistry*, 1998, 63, 1109) can be employed, as shown in Scheme 7. Thus, an ester
30 of the general formula **IV** ($R^3 = O\text{-alkyl}$) is reacted with a cyclic lactam of the general formula XXX



where L^4 is a reaction labile group such as $-CH=CH_2$, in the presence of a strong base such as sodium methoxide, to produce the intermediate of general formula **XXI**. This intermediate can then be converted to the corresponding cyclic imine of formula **XXII** in the presence of a strong acid, such as hydrochloric acid, usually under reflux conditions. Subsequently, the 5 compounds of formula **XXII** can be reduced to form the cyclic amines of formula **XXIII** (wherein $R^1 = H$) using, for example, sodium borohydride in methanol as described previously. Such compounds of formula **XXIII** can further be converted into compounds of the formula **XXIII** (wherein R^1 is as defined for compounds of formula I) as previously discussed.

The *in vitro* activity of the compounds of the present invention at the individual 10 monoamine reuptake sites can be determined using rat synaptosomes or HEK-293 cells transfected with the human serotonin, dopamine or norepinephrine transporter, according to the following procedure adapted from those described by S. Snyder *et al.*, (Molecular Pharmacology, 1971, 7, 66-80), D.T. Wong *et al.*, (Biochemical Pharmacology, 1973, 22, 311-322), H. F. Bradford (Journal of Neurochemistry, 1969, 16, 675-684) and D. J. K. Balfour 15 (European Journal of Pharmacology, 1973, 23, 19-26).

Synaptosomes: Male Sprague Dawley rats are decapitated and the brains rapidly removed. The cortex, hippocampi and corpus striata are dissected out and placed in ice cold sucrose buffer, 1 gram in 20 ml of buffer (the buffer is prepared using 320 mM sucrose containing 1mg/ml glucose, 0.1mM ethylenediamine tetraacetic acid (EDTA) adjusted to pH 20 7.4 with tris(hydroxymethyl)-aminomethane (TRIS) base). The tissues are homogenized in a glass homogenizing tube with a Teflon™ pestle at 350 rpm using a Potters homogenizer. The homogenate is centrifuged at 1000 x g for 10 min. at 4°C. The resulting supernatant is recentrifuged at 17,000 x g for 20 min. at 4°C. The final pellet is resuspended in an appropriate volume of sucrose buffer that yielded less than 10% uptake.

25 Cell Preparation: HEK-293 cells transfected with the human serotonin (5-HT), norepinephrine (NE) or dopamine (DA) transporter are grown in DMEM (Dulbecco's Modified Eagle Medium, Life Technologies Inc., 9800 Medical Center Dr., Gaithersburg, MD, catalog no. 11995-065)) supplemented with 10% dialyzed FBS (Fetal Bovine Serum, from Life Technologies, catalog no. 26300-053), 2 mM L-glutamine and 250 ug/ml G418 for the 5-HT 30 and NE transporter or 2ug/ml puromycin for the DA transporter, for selection pressure. The cells are grown in Gibco triple flasks, harvested with Phosphate Buffered Saline (Life Technologies, catalog no. 14190-136) and diluted to an appropriate amount to yield less than 10% uptake.

35 Neurotransmitter Uptake Assay: The uptake assays are conducted in glass tubes containing 50 uL of solvent, inhibitor or 10uM sertraline, desipramine or nomifensine for the 5-HT, NE or DA assay nonspecific uptake, respectively. Each tube contains 400 uL of [3H]5-HT

(5 nM final), [3H]NE (10 nM final) or [3H]DA (5 nM final) made up in modified Krebs solution containing 100 uM pargyline and glucose (1mg/ml). The tubes are placed on ice and 50 uL of synaptosomes or cells is added to each tube. The tubes are then incubated at 37° C for 7 min. (5-HT, DA) or 10 min. (NE). The incubation is terminated by filtration (GF/B filters), using
5 a 96-well Brandel Cell Harvester, the filters are washed with modified Krebs buffer and counted using either a Wallac Model 1214 or Wallac Beta Plate Model 1205 scintillation counter.

EXPERIMENTAL EXAMPLESPREPARATION 12-(3,4-DICHLOROPHOXY)-5-TRIFLUOROMETHYLBENZALDEHYDE

Under N₂ in a 50 mL round-bottomed flask fitted with a reflux condenser and magnetic stirrer were placed 0.829 g (6.0 mmol) of K₂CO₃ and 0.342 g (2.1 mmol) of 3,4-dichlorophenol (Aldrich Chem. Co., Milwaukee, WI) in 10 mL of anhydrous N,N-dimethylformamide (DMF). After stirring the mixture for 5 min., 0.384 g (2.0 mmol) of 2-fluoro-5-trifluoromethylbenzaldehyde (Aldrich) was added and the mixture was heated to 90-95° C overnight. After allowing the reaction to cool to room temperature, the mixture was diluted with water and EtOAc, the aqueous layer was extracted with additional EtOAc and the organic layers were combined, washed with H₂O and saturated NaCl and dried over MgSO₄. Removal of the solvent in vacuo gave a light amber colored oil, 0680 g.

¹H-NMR (CDCl₃, 400 MHz): d 10.46 (s, 1H), 8.18 (s, 1H), 7.74 (m, 1H), 7.48 (m, 1H), 7.23 (m, 1H), 6.97 (m, 2H).

15 Mass spectrum (GCMS, m/z): 334 (m⁺).

In the same manner, the following aldehyde and ketone intermediates of the formula IV were prepared:

Prep. No.	X _(n)	Y _(m)	R ³	yield (%)	m.p. (°C)	m/z (m ⁺)	¹ H-NMR (CDCl ₃ , δ)
2	H	3,4-Cl ₂	H	35	57-58	269, 267	(s, 1H), 7.94 (d, 1H), 7.56 (m, 1H), 7.42 (d, 1H), 7.24 (m, 1H), 7.15 (s, 1H), 6.90 (m, 2H).
3	5-F	4-Cl	H	57	oil	252, 250	(s, 1H), 7.58 (dd, 1H), 7.33 (m, 2H), 7.23 (m, 1H), 6.95 (m, 1H), 6.90 (dd, 1H).
4	H	4-Cl	H	71	oil	234, 232	(s, 1H), 7.92 (dd, 1H), 7.51 (m, 1H), 7.33 (m, 2H), 7.22 (t, 1H), 7.00 (m, 2H), 6.87 (dd, 1H).

Prep. No.	X _(n)	Y _(m)	R ³	yield (%)	m.p. (°C)	m/z (m ⁺)	¹ H-NMR (CDCl ₃ , δ)
5	5-F	3,4-Cl ₂	H	67	oil	286, 284	(d, 1H), 7.60 (dd, 1H), 7.42 (d, 1H), 7.28 (m, 1H), 7.10 (d, 1H), 6.95 (dd, 1H), 6.87 (dd, 1H).
6	5-F	3,4- (OCH ₂ O)	H	38	oil	270	(s, 1H), 7.57 (m, 1H), 7.20 (m, 1H), 7.18 (m, 1H), 7.04 (d, 1H), 6.88 (m, 1H), 6.73 (m, 2H), 2.72 (m, 4H), 1.78 (m, 4H).
7	5-CF ₃	3,4-Cl ₂	H	98	oil	336, 334	(s, 1H), 8.18 (s, 1H), 7.74 (m, 1H), 7.48 (m, 1H), 7.23 (m, 1H), 6.97 (m, 2H).
8	5-NO ₂	3,4-Cl ₂	H	20	oil	313, 311	(s, 1H), 8.78 (d, 1H), 8.35 (dd, 1H), 7.54 (d, 1H), 7.25 (m, 1H), 7.02 (dd, 1H), 6.94 (d, 1H).
9	3-CF ₃	3,4-Cl ₂	H	98	oil	336, 334	(s, 1H), 8.16 (dd, 1H), 7.99 (dd, 1H), 7.54 (t, 1H), 7.34 (d, 1H), 6.92 (d, 1H), 6.6 (dd, 1H).
10	H	3,4-Cl ₂	CH ₃	17	oil	284, 282	(dd, 1H), 7.46 (dt, 1H), 7.39 (d, 1H), 7.24 (dt, 1H), 7.21 (d, 1H), 7.08 (d, 1H), 6.92 (dd, 1H), 6.83 (dd, 1H), 2.57 (s, 3H).

Prep. No.	X _(n)	Y _(m)	R ³	yield (%)	m.p. (°C)	m/z (m ⁺)	¹ H-NMR (CDCl ₃ , δ)
11	H	4-CH ₃	H	69	oil	212	(s, 1H), 7.46 (m, 1H), 7.15 (m, 3H), 6.96 (m, 2H), 6.84 (d, 1H), 2.34 (s, 3H).
12	4-CF ₃	3,4-Cl ₂	H	44	oil	338, 336	(s, 1H), 8.05 (d, 1H), 7.49 (d, 2H), 7.22 (m, 1H), 7.13 (s, 3H), 6.94 (dd, 1H).
13	H	3,4-F ₂	H	68	oil	234	(s, 1H), 7.93 (dd, 1H), 7.53 (dt, 1H), 7.23 (d, 1H), 7.17 (t, 1H), 6.89 (m, 2H), 6.78 (m, 1H).
14	H	4-CH ₃	CH ₃	19	oil	227	(dd, 1H), 7.38 (m, 1H), 7.13 (m, 3H), 6.86 (m, 3H), 2.63 (s, 3H), 2.33 (s, 3H).
15	6-CF ₃	3,4-Cl ₂	H	79	oil	336, 334	(s, 1H), 7.59 (m, 2H), 7.42 (dd, 1H), 7.14 (dd, 1H), 7.12 (m, 1H), 6.87 (m, 1H).
16	5-F	3,4-(CH ₃) ₂	H	53	oil	244	(s, 1H), 7.57 (dd, 1H), 7.19 (m, 1H), 7.11 (d, 1H), 6.87 (dd, 1H), 6.81 (m, 1H), 6.75 (dd, 1H), 2.24 (s, 6H).
17	H	3,4-(CH ₃) ₂	H	60	oil	226	(s, 1H), 7.91 (dd, 1H),

Prep. No.	X _(n)	Y _(m)	R ³	yield (%)	m.p. (°C)	m/z (m ⁺)	¹ H-NMR (CDCl ₃ , δ)
							7.89 (d, 1H), 7.46 (dt, 1H), 7.11 (m, 2H), 6.85 (m, 2H), 6.79 (dd, 1H), 2.24 (s, 6H).
18	4-CF ₃	3,4-Cl ₂	H	37	oil	336, 334	(s, 1H), 8.04 (d, 1H), 7.48 (m, 2H), 7.20 (s, 1H), 7.13 (s, 1H), 6.94 (dd, 1H).
19	4-Cl	3,4-Cl ₂	H	55	oil	302, 300	(s, 1H), 7.86 (d, 1H), 7.46 (d, 1H), 7.19 (m, 2H), 6.94 (dd, 1H), 6.86 (d, 1H).
20	5-F	3,4-(OCH ₂ O)	H	19	oil	260	(s, 1H), 7.56 (dd, 1H), 7.19 (m, 1H), 6.86 (dd, 1h), 6.77 (d, 1H), 6.58 (s, 1H), 6.47 (d, 1H), 5.99 (s, 2H).
21	3-F	3,4-Cl ₂	H	63	foam	286, 284	(s 1H), 7.76 (d, 1H), 7.41 (m, 3H), 6.81 (s, 1H), 6.80 (s, 1H).
22	5-F	3,4-Cl ₂	CH ₃	15	foam	300, 298	(dd, 1H), 7.40 (d, 1H), 7.20 (m, 1H), 7.05 (d, 1H), 6.94 (dd, 1H), 6.80 (dd, 1H), 2.55 (s, 3H).
23	5-F	4-Cl	CH ₃	27	foam	266, 264	(dd, 1H), 7.30 (d, 2H), 7.15 (dt, 1H), 6.89 (d, 2H), 2.57 (s, 3H).

Prep. No.	X _(n)	Y _(m)	R ³	yield (%)	m.p. (°C)	m/z (m ⁺)	¹ H-NMR (CDCl ₃ , δ)
24	4-F	3,4-Cl ₂	H	41	oil	286, 284	10.2 (s, 1H), 7.85 (m, 1H), 7.47 (d, 1H), 7.22 (d, 1H), 6.95 (m, 1H), 6.82 (m, 1H), 6.68 (m, 1H).
25	5-OCH ₃	3,4-Cl ₂	H	9	oil	298, 296	(s, 1H), 7.38 (m, 2H), 7.15 (M, 1h), 7.05 (S, 1h), 6.94 (D, 1h), 6.83 (DD, 1h), 3.84 (S, 3h).
26	H	4-Cl	CH3	29	oil	248, 246	(d, 1H), 7.43 (dt, 1H), 7.31 (s, 1H), 7.29 (s, 1H), 7.21 (t, 1H), 6.92 (d, 1H), 6.88 (d, 1H), 2.60 (s, 3H).
27	5-F	4-Cl	H	60	oil	252, 250	(s, 1H), 7.59 (dd, 1H), 7.33 (m, 2H), 7.23 (m, 1H), 6.94 (m, 3H).
28	4,5-(OCH ₃) ₂	3,4-Cl ₂	H	40	oil	328, 326	(s, 1H), 7.25 (m, 1H), 7.07 (dd, 1H), 6.95 (dd, 1H), 6.85 (dd, 1H), 6.83 (dd, 1H), 3.92 (s, 3H), 3.85 (s, 3H)
29	4,5-(CH ₃) ₂	3,4-Cl ₂	H	29	oil	296, 294	(s, 1H), 7.67 (s, 1H), 7.38 (d, 1H), 7.07 (s, 1H), 6.85 (m, 1H), 6.71 (s, 1H), 2.26 (d, 6H).
30	5-Br	3,4-Cl ₂	H	90	129- 132	346, 344	10.4 (s, 1H), 8.03 (d, 1H), 7.64 (dd, 1H), 7.45 (dd, 1H), 7.15 (d, 1H),

Prep. No.	X _(n)	Y _(m)	R ³	yield (%)	m.p. (°C)	m/z (m ⁺)	¹ H-NMR (CDCl ₃ , δ)
							6.91 (dd, 1H), 6.89 (dd, 1H)
31	4-Br	3,4-Cl ₂	H	47	solid	346, 344	(s, 1H), 7.79 (dd, 1H), 7.47 (m, 1H), 7.37 (m, 1H), 7.19 (m, 1H), 7.03 (m, 1H), 6.94 (m, 1H).

PREPARATION 325-CYANO-2-(3,4-DICHLOROPHOENOXY)-BENZALDEHYDE

Under N₂ in a flame-dried 3-neck round bottomed flask fitted with a reflux condenser and magnetic stirrer, a mixture of 5-bromo-2-(3,4-dichlorophenoxy)-benzaldehyde (3.0 g, 8.7 mmol), zinc (II) cyanide (1.5 g, 13 mmol) and tetrakis(triphenylphosphine) palladium (0) (1.5 g, 1.3 mmol) in anhydrous DMF (145 ml) was stirred at room temperature while degassing with N₂ for 5 min. After heating at approximately 80 °C for 90 min., the reaction was judged complete by thin layer chromatography (50% CH₂Cl₂:hexanes) and was allowed to cool to room temperature. The reaction mixture was then diluted with water and ethyl acetate (EA) and stirred another 10 min. The water layer was separated, extracted twice with EA and combined with the original EA layer, and washed with an aqueous solution of Rochelle salt (potassium sodium tartrate tetrahydrate) followed by aqueous NaCl. The organic layer was dried with Na₂SO₄, filtered and concentrated in vacuo to an oil. The oil was flash chromatographed on a 15 X 5 cm column of silica gel, eluting with CH₂Cl₂:hexanes (1:1) to obtain the title product as a white solid, 1.5 g (60%), m.p. 122-126 °C.

Mass spectrum (GC/MS, m/z): 291 (m⁺), 262.

¹H-NMR (CDCl₃, d): 10.47 (s, 1H), 8.22 (d, 1H), 7.75 (dd, 1H), 7.53 (d, 1H), 7.25 (m, 1H), 6.98 (dd, 1H), 6.92 (d, 1H).

In the same manner, **4-cyano-2-(3,4-dichlorophenoxy)-benzaldehyde** was prepared from the corresponding 4-bromo-2-(3,4-dichlorophenoxy)-benzaldehyde, clear oil, 16%. Mass spectrum (GC/MS, m/z): 291 (m⁺). ¹H-nmr (CDCl₃, d): 10.45 (s, 1H), 8.02 (d, 1H), 7.55 (m, 2H), 7.23 (m, 1H), 7.14 (m, 1H), 6.96 (dd, 1H).

PREPARATION 334,5-DIMETHOXY-2-FLUOROBENZALDEHYDE

In a flame-dried, round-bottomed flask fitted with a magnetic stirrer and N₂ inlet was placed 4-fluoroveratrole (0.78 g, 5.0 mmol, Aldrich Chemical Co.) in 20 ml of anhydrous

CH_2Cl_2 . After cooling to 0° C, titanium (IV) chloride (0.91 ml, 1.57 g, 8.3 mmol) was added, followed after 10 min. by a,a-dichloromethyl methyl ether (0.45 ml, 0.575 g, 5.0 mmol). The mixture was allowed to warm to room temperature and after 2 hr it was quenched with an excess of aqueous saturated NaHCO_3 . The suspension was filtered through a pad of d.e. 5 (diatomaceous earth), the aqueous phase was extracted with additional amounts of CH_2Cl_2 and the organic phases were combined and washed with water followed by saturated aqueous NaCl . After drying with MgSO_4 , the organic solvent was removed in vacuo to give the title compound as a white solid, 910 mg.

$^1\text{H-NMR}$ (CDCl_3 , d): 10.2 (s, 1H), 7.26 (d, 1H), 6.64 (d, 1H), 3.93 (s, 3H), 3.89 (s, 3H).

10

PREPARATION 34

2-(3,4-DICHLOROPHOXY)-5-BENZONITRILE

Under N_2 in a single-neck round bottomed flask with a reflux condenser and magnetic stirrer, a mixture of 3,4-dichlorophenol (1.96 g, 12 mmol) and anhydrous potassium carbonate (4.14 g, 30 mmol) in anhydrous N,N-dimethylformamide (DMF, 50 ml) was treated with 2,5-difluorobenzonitrile (1.39 g, 10 mmol, Aldrich Chemical Co., Milwaukee, WI) and heated to 95-15 100 °C for 18 hr. The mixture was then cooled to room temperature and diluted with water and ethyl acetate (EA), the water layer was extracted with additional quantities of EA and the EA layers were combined, washed with water, 2N NaOH, water and finally saturated aqueous NaCl. After drying over MgSO_4 , the solvent was removed in vacuo to give a tan solid.

20 Mass spectrum (GC/MS): m/z 281 (m⁺).

$^1\text{H-NMR}$ (CDCl_3 , 300 MHz, d): 7.43 (d, 1H), 7.37 (dd, 1H), 7.26 (m, 1H), 7.12 (d, 1H), 6.92 (m, 2H).

In a similar fashion, the following benzonitriles of the formula VI were prepared, isolated after flash chromatography (silica gel, elution with 20% CH_2Cl_2 in hexanes):

Prep. No.	X	Y	Yield, %	m/z, m ⁺	$^1\text{H-NMR}$ (CDCl_3 , δ)
35	5- CH_3	3,4- Cl_2	24	279, 277	(bs, 1H), 7.40 (d, 1H), 7.30 (dd, 1H), 7.10 (d, 1H), 6.87 (m, 2H), 2.34 (s, 3H).
36	4- OCH_3	3,4- Cl_2	46	295, 293	(d, 1H), 7.44 (d, 1H), 7.17 (d, 1H), 6.94 (dd, 1H), 6.70 (dd, 1H), 6.37 (d, 1H), 3.78 (s, 3H).
37	H	3,4- Cl_2	98	265, 263	(dd, 1H), 7.52 (t, 1H), 7.44 (d, 1H),

Prep. No.	X	Y	Yield, %	m/z, m+	¹ H-NMR (CDCl ₃ , δ)
					7.20 (m, 2H), 6.92 (m, 2H).

PREPARATION 38**2-(3,4-DICHLOROPHOXY)-5-FLUORO-N-METHYL-BENZAMIDE**

- A mixture of 0.602 g (2.0 mmol) of 2-(3,4-dichlorophenoxy)-5-fluoro-benzoic acid in 20 mL of
 5 anhydrous benzene was treated with 2 drops of N,N-dimethylformamide (DMF), followed by slow addition of 0.785 g (481 µL, 6.6 mmol) of thionyl chloride. After heating to reflux for 3.5 hr, the solution was stirred at room temperature overnight and concentrated in vacuo to a tan oil that was further azeotroped twice with fresh benzene. The residue was re-dissolved in 4 mL of benzene and added to 15 mL of 1.0 M CH₃NH₂ in CH₃OH (Aldrich Chem. Co.) at 25 °C.
 10 After 12 hr, the mixture was concentrated in vacuo and partitioned between water and EtOAc. The aqueous layer was then extracted with additional EtOAc and the combined organic extracts were washed with water followed by saturated aqueous NaCl, dried with MgSO₄, filtered and concentrated to a brown oil which slowly solidified on standing, 0.654 g.
 15 ¹H-nmr (CDCl₃, 400 MHz, δ): 7.89 (dd, 1H), 7.41 (d, 1H), 7.30 (bs, 1H, NH), 7.09 (m, 2H), 6.83 (m, 2H), 2.95 (d, 3H).

PREPARATION 39**2-(3,4-DICHLOROPHOXY)-5-FLUORO-BENZONITRILE**

- A flame-dried flask containing N₂ inlet and magnetic stirrer was charged with 2.9 g (18 mmol) of 3,4-dichlorophenol, 6.2 g (45 mmol) of potassium carbonate and 50 mL of anhydrous DMF. With stirring, 2.08 g (15 mmol) of 2,5-difluorobenzonitrile (Aldrich Chem. Co.) was added and the mixture was heated overnight at 105 °C, cooled to room temperature and partitioned between water and EtOAc. The aqueous layer was reextracted with EtOAc and the combined organic layers were successively washed with 2N NaOH, water and saturated aqueous NaCl. After drying with MgSO₄, the solvent was removed to give the title product as a light brown oil which slowly solidified, 3.5 g.

Mass spectrum (APCI, m/z): 281 (m⁺).

¹H-nmr (CDCl₃, 400 MHz, δ): 7.43 (d, 1H), 7.37 (dd, 1H), 7.26 (m, 1H), 7.12 (d, 1H), 6.92 (m, 2H).

PREPARATION 402-(3,4-DICHLOROPHOENOXY)-5-FLUORO-BENZALDEHYDE

A flame-dried flask containing N₂ inlet and magnetic stirrer was charged with 1.24 g (9.0 mmol) of potassium carbonate and 20 mL of anhydrous DMF, followed by 0.513 g (3.15 mmol) of 3,4-dichlorophenol, with stirring at room temperature. After 5 min, 0.426 g (3.0 mmol) of 2,5-difluorobenzaldehyde (Aldrich Chem. Co.) was added and the mixture was heated at 95 °C for 18 hr. After cooling to room temperature, the mixture was diluted with water, twice extracted with EtOAc and the organic extracts were washed with water and saturated NaCl and dried over MgSO₄. Removal of the solvent gave a brown oil, 963 mg, which was chromatographed on 230-400 mesh silica eluted with 5% EtOAc:95% hexanes.

The title product was isolated from the appropriate fractions as a white low-melting solid, 0.572 g.

¹H-nmr (CDCl₃, 400 MHz, δ): 7.60 (dd, 1H), 7.42 (d, 1H), 7.28 (m, 1H), 7.10 (d, 1H), 6.95 (dd, 1H), 6.87 (dd, 1H).

15

EXAMPLE 12-FLUORO-6-(P-TOLYLOXY)BENZYLAMINE

A flame-dried flask containing N₂ inlet and magnetic stirrer was charged with 6.0 mL of 1.0 M lithium aluminum hydride in THF (6.0 mmol, Aldrich Chem. Co.), followed by an additional 10 mL of anhydrous THF at room temperature. While stirring, 0.341 g (1.5 mmol) of 2-fluoro-6-(p-tolyloxy)benzonitrile (Maybridge Chem. Co. Ltd., Trevillett, Tintagel, Cornwall, UK) was added slowly via syringe, causing some mild foaming. After 4 hr, a tlc (CHCl₃:CH₃OH, 95:5) showed no starting material and two new very polar spots. With ice bath cooling, the reaction was quenched using 230 mL H₂O, 230 mL 15% NaOH and then 690 mL H₂O. After 15 min stirring at room temperature, the mixture was filtered through a d.e. pad, the pad was washed further with small amounts of CH₂Cl₂ and the combined organic filtrate was concentrated in vacuo to a yellow oil, 0.287 g. The oil was chromatographed on 10 g silica gel (230-400 mesh) eluting first with CH₂Cl₂, then adding increasing percentages of CH₃OH. The less polar of the two spots, **2-Fluoro-6-(p-tolyloxy)benzylamine** eluted as a yellow oil, 0.120 g.

Mass spectrum (APCI, m/z): 232 (m⁺), 215 (m⁺-NH₃)

¹H-NMR (CDCl₃, 400 MHz): d 7.12 (m, 3H), 6.86 (m, 2H), 6.78 (t, 1H), 6.60 (dd, 1H), 3.92 (s, 2H), 2.32 (s, 3H), 1.72 (bs, 2H, NH₂).

Further elution of the chromatography provided the more polar component, **2-(p-tolyloxy)benzylamine**, as a yellow oil, 0.082 g.

¹H-NMR (CDCl₃, 400 MHz): δ 7.34 (d, 1H), 7.12 (m, 4H), 6.86 (m, 3H), 3.87 (s, 2H), 2.31 (s, 3H), 1.80 (bs, 2H, NH₂).

- 5 By the same method, the following benzylamino compounds of formula I (where R¹⁻⁴ = H) were prepared from the corresponding benzonitriles VI:

Ex. No.	X	Y	yield (%)	m.p., °C (HCl salt)	m/z, m ⁺	¹ H-NMR (DMSO-d ₆ , δ)
2	H	3,4-Cl ₂	87	198-201	270, 268	(bs, 1H, HCl), 7.65 (d, 1H), 7.59 (d, 1H), 7.36 (m, 2H), 7.22 (t, 1H), 7.06 (dd, 1H), 6.92 (d, 1H), 4.00 (s, 2H).
3	5-F	3,4-Cl ₂	67	190-194	288, 286	(d, 1H), 7.52 (dd, 1H), 7.31 (s, 1H), 7.23 (dt, 1H), 7.03 (m, 2H), 3.99 (bs, 2H).
4	5-CH ₃	3,4-Cl ₂	54	217-219	284, 282	(d, 1H), 7.38 (s, 1H), 7.22 (d, 1H), 7.20 (m, 1H), 6.99 (m, 1H), 6.87 (d, 1H), 3.94 (bs, 2H), 2.28 (s, 3H).
5	4-OCH ₃	3,4-Cl ₂	37	167-168	300, 298	(d, 1H), 7.52 (d, 1H), 7.35 (d, 1H), 7.06 (dd, 1H), 6.82 (dd, 1H), 6.45 (d, 1H), 3.90 (m, 2H), 3.68 (s, 3H).

EXAMPLE 6[2-(3,4-DICHLOROPHOXY)-5-TRIFLUOROMETHYLBENZYL]-DIMETHYLAMINEMALEATE

In a round-bottomed flask fitted with a magnetic stirrer and N₂ inlet was placed 0.331 g (4.06 mmol) of dimethylamine hydrochloride (Aldrich) and 0.410 g (4.06 mmol) triethylamine in 25 mL ethanol while stirring until the solution was clear. At room temperature, 1.15 g titanium (IV) isopropoxide (1.2 mL, 4.06 mmol) was added via syringe, followed by 0.680 g (2.03 mmol) of 2-(3,4-dichlorophenoxy)-5-trifluoromethyl-benzaldehyde to give a yellow-brown solution which was stirred overnight. To the resulting cloudy solution was added 0.115 g (3.05 mmol) of sodium borohydride, and stirring was continued for 24 hr. The reaction was then quenched with 6N HCl (~pH = 10), stirred another 2 hr and diluted with EtOAc. The aqueous layer was made basic with saturated aqueous Na₂CO₃, layered with additional EtOAc and the two-layered mixture was filtered through a pad of diatomaceous earth (d.e.), washing the d.e. pad well with EtOAc and H₂O. The EtOAc layer was combined with additional extracts of the water layer and the combined organics were washed with saturated aqueous NaCl, dried with MgSO₄ and concentrated in vacuo to a yellow oil, 0.626 g.

Mass spectrum: (APCI, m/z) 366, 364 (m⁺).

¹H-NMR (CDCl₃, 400 MHz): δ 7.78 (s, 1H), 7.47 (dd, 1H), 7.39 (s, 1H), 7.04 (s, 1H), 6.90 (dd, 1H), 6.80 (dd, 1H), 3.48 (s, 2H), 2.26 (s, 6H).

The preceding oil dissolved in anhydrous diethyl ether was treated with 0.199 g of maleic acid in 2 mL of acetone. The mixture was filtered through a thin pad of d.e. to clarify the solution and then was stirred at room temperature for 8 hr. The resulting solids were filtered and washed with Et₂O and dried under vacuum, m.p 127-128 °C.

Elemental analysis for C₁₆H₁₄Cl₂F₃NO•C₄H₄O₄ calculated: C, 50.01, H, 3.77, N, 2.92.

Found: C, 49.93, H, 3.85, N, 3.04.

In the same manner the following compounds of formula I, wherein R⁴ is hydrogen, were prepared:

Ex. No.	X	Y	R ³	NR ¹ R ²	mp, °C	m/z, m ⁺	Elemental Analysis formula calculated:CHN found
7	H	3,4-Cl ₂	H	N(CH ₃) ₂	173- 174	298, 296	C ₁₅ H ₁₅ Cl ₂ NO•HCl•H 2O C 54.16, H 4.85, N 4.21: C 54.02, H

Ex. No.	X	Y	R ³	NR ¹ R ²	mp, °C	m/z, m ⁺	Elemental Analysis formula CHN calculated:CHN found
							4.77, N 4.23
8	H	3,4-Cl ₂	H	NHCH ₃	126	284, 282	C ₁₄ H ₁₃ Cl ₂ NO•¾ C ₄ H ₄ O ₄ C 54.42, H 4.48, N 3.73; C 54.46, H 4.48, N 3.52
9	H	3,4-Cl ₂	H	NHC ₂ H ₅	133- 135	298, 296	C ₁₅ H ₁₅ Cl ₂ NO• C ₄ H ₄ O ₄ C 55.35, H 4.65, N 3.40; C 55.16, H 4.68, N 3.40
10	5-F	4-Cl	H	NHCH ₃	208- 209	268, 266	C ₁₄ H ₁₃ CIFNO•HCl C 55.64, H 4.66, N 4.63; C 55.64, H 4.52, N 4.55
11	H	4-Cl	H	N(CH ₃) ₂	122	264, 262	C ₁₅ H ₁₆ CINO• C ₄ H ₄ O ₄ C 60.40, H 5.33, N 3.70; C 60.46, H 5.29, N 3.71
12	H	4-Cl	H	NHCH ₃	128- 129	250, 248	C ₁₄ H ₁₄ CINO•C ₄ H ₄ O ₄ •1/3H ₂ O C 58.46, H 5.09, N 3.79; C 58.26, H 4.87, N 3.89
13	5-F	3,4-Cl ₂	H	N(CH ₃) ₂	174- 175	316, 314	C ₁₅ H ₁₄ Cl ₂ FNO•HCl C 51.38, H 3.89, N 4.16; C 51.35, H 4.22, N 3.91
14	5-F	3,4-Cl ₂	H	NHCH ₃	202- 203	302, 300	C ₁₄ H ₁₂ Cl ₂ FNO•HCl C 49.95, H 3.89, N

Ex. No.	X	Y	R ³	NR ¹ R ²	mp, °C	m/z, m ⁺	Elemental Analysis formula CHN calculated:CHN found
							4.16: C 50.05, H 4.04, N 4.21
15	5-F	3,4-Cl ₂	H	NHCH ₃	129- 130	302, 300	C ₁₄ H ₁₂ Cl ₂ FNO• ½ C ₄ H ₄ O ₄ C 50.48, H 4.37, N 3.68: C 50.24, H 4.37, N 3.68
16	5-NO ₂	3,4-Cl ₂	H	N(CH ₃) ₂		343, 341	Not determined
17	3-CF ₃	3,4-Cl ₂	H	N(CH ₃) ₂	229- 230	366, 364	C ₁₆ H ₁₄ Cl ₂ F ₃ NO•HCl• H ₂ O C 45.90, H 4.09, N 3.35: C 45.70, H 3.82, N 3.30
18	H	3,4-Cl ₂	CH ₃	N(CH ₃) ₂	130- 133	312, 310	C ₁₆ H ₁₇ Cl ₂ NO•HCl Not determined
19	H	4-CH ₃	H	N(CH ₃) ₂	111- 113	242	C ₁₆ H ₁₉ NO• C ₄ H ₄ O ₄ • ¼ H ₂ O C 66.38, H 6.55, N 3.87: C 66.47, H 6.40, N 3.95
20	4-CF ₃	3,4-Cl ₂	H	N(CH ₃) ₂	131- 133	366, 364	C ₁₆ H ₁₄ Cl ₂ F ₃ NO•C ₄ H ₄ O ₄ • 2/3 H ₂ O C 48.80, H 3.96, N 2.85: C 48.85, H 3.77, N 2.97
21	H	3,4-F ₂	H	N(CH ₃) ₂	145- 147	264	C ₁₅ H ₁₅ F ₂ NO• C ₄ H ₄ O ₄ C 60.15, H 5.05, N 3.69: C 60.09, H

Ex. No.	X	Y	R ³	NR ¹ R ²	mp, °C	m/z, m ⁺	Elemental Analysis formula CHN calculated:CHN found
							4.91, N 3.74
22	H	3,4-F ₂	H	NHCH ₃	101- 102	250	C ₁₄ H ₁₃ F ₂ NO• C ₄ H ₄ O ₄ C 59.17, H 4.69, N 3.83: C 59.04, H 4.82, N 3.93
23	H	4-CH ₃	CH ₃	NHCH ₃	114- 116	242	C ₁₆ H ₁₉ NO•C ₄ H ₄ O ₄ •1 /8H ₂ O C 66.79, H 6.52, N 3.89: C 66.82, H 6.58, N 3.95
24	6-CF ₃	3,4-Cl ₂	H	N(CH ₃) ₂	166- 168	366, 364	C ₁₆ H ₁₄ Cl ₂ F ₃ NO•HCl C 47.96, H 3.77, N 3.49: C 47.95, H 3.81, N 3.48
25	6-CF ₃	3,4-Cl ₂	H	NHCH ₃	123- 125	352, 350	C ₁₅ H ₁₂ C ₁₂ F ₃ NO• C ₄ H ₄ O ₄ C 48.94, H 3.45, N 3.00: C 48.90, H 3.58, N 3.23
26	5-F	3,4- (CH ₃) ₂	H	NHCH ₃	123- 124	260	C ₁₆ H ₁₈ FNO• C ₄ H ₄ O ₄ C 63.99, H 5.91, N 3.73: C 63.89, H 5.91, N 3.760
27	H	3,4- (CH ₃) ₂	H	NHCH ₃	118- 119	242	C ₁₆ H ₁₉ NO• C ₄ H ₄ O ₄ C 67.20, H 6.48, N 3.91: C 66.91, H 6.48, N 3.96

Ex. No.	X	Y	R ³	NR ¹ R ²	mp, °C	m/z, m ⁺	Elemental Analysis formula CHN calculated:CHN found
28	4-CF ₃	3,4-Cl ₂	H	NHCH ₃	164- 166	352, 350	C ₁₅ H ₁₂ Cl ₂ F ₃ NO• C ₄ H ₄ O ₄ C 48.94, H 3.46, N 3.00: C 49.02, H 3.22, N 3.06
29	4-Cl	3,4-Cl ₂	H	NHCH ₃	132- 133	318, 316	C ₁₄ H ₁₂ Cl ₃ NO• C ₄ H ₄ O ₄ C 49.96, H 3.72, N 3.24: C 49.89, H 3.49, N 3.25
30	5-F	3,4- (OCH ₂ O)	H	NHCH ₃	96-97	276	C ₁₅ H ₁₄ NO ₃ • C ₄ H ₄ O ₄ C 58.31, H 4.63, N 3.57: C 58.34, H 4.38, N 3.62
31	3-F	3,4-Cl ₂	H	NHCH ₃	138- 140	302, 300	C ₁₄ H ₁₂ Cl ₂ FNO• C ₄ H ₄ O ₄ C 51.94, H 3.87, N 3.36: C 51.96, H 3.87, N 3.44
32	5-F	3,4-Cl ₂	CH ₃	NHCH ₃	127	316, 314	C ₁₅ H ₁₄ Cl ₂ FNO• C ₄ H ₄ O ₄ C 53.04, H 4.22, N 3.25: C 53.23, H 4.21, N 3.23
33	5-F	4-Cl	CH ₃	NHCH ₃	173- 175	282, 280	C ₁₅ H ₁₅ ClFNO•HCl C 56.98, H 5.10, N 4.43: C 56.90, H 5.34, N 4.42
34	4-F	3,4-Cl ₂	H	NHCH ₃	151- 152		C ₁₄ H ₁₂ Cl ₂ FNO• C ₄ H ₄ O ₄ C 50.31, H 4.10, N 3.26: C

Ex. No.	X	Y	R ³	NR ¹ R ²	mp, °C	m/z, m ⁺	Elemental Analysis formula CHN calculated:CHN found
							50.28, H 3.93, N 3.24
35	5-OCH ₃	3,4-Cl ₂	H	NHCH ₃	140- 141	314, 312	C ₁₅ H ₁₅ Cl ₂ NO ₂ •HCl•1 /4 H ₂ O C 51.01, H 4.71, N 3.97: C 51.08, H 4.54, N 3.91
36	H	4-Cl	CH ₃	NHCH ₃	147- 149	264, 262	C ₁₅ H ₁₆ ClNO•HCl C 60.41, H 5.74, N 4.69: C 60.02, H 5.74, N 4.65
37	5-F	4-Cl	H	N(CH ₃) ₂	103	282, 280	C ₁₅ H ₁₅ ClFNO• C ₄ H ₄ O ₄ C 57.65, H 4.83, N 3.53: C 57.74, H 4.82, N 3.47
38	4,5- (OCH ₃) ₂	3,4-Cl ₂	H	NHCH ₃	143- 145	344, 342	C ₁₆ H ₁₇ Cl ₂ NO ₃ •HCl C 47.37, H 5.20, N 3.45: C 47.36, H 4.93, N 3.49
39	4,5- (CH ₃) ₂	3,4-Cl ₂	H	NHCH ₃		312, 310	C ₁₆ H ₁₇ Cl ₂ NO•HCl C 55.43, H 5.23, N 4.04: C 55.84, H 4.80, N 3.80
40	5-Br	3,4-Cl ₂	H	NHCH ₃	206- 210	364, 362	C ₁₄ H ₁₂ BrCl ₂ NO•HCl C 42.30, H 3.30, N 3.52: C 42.13, H 3.13, N 3.36
41	4-Br	3,4-Cl ₂	H	NHCH ₃	185- 189	364, 362	C ₁₄ H ₁₂ BrCl ₂ NO•HCl C 42.30, H 3.30, N 3.52: C 42.03, H

Ex. No.	X	Y	R ³	NR ¹ R ²	mp, °C	m/z, m ⁺	Elemental Analysis formula CHN calculated:CHN found
							3.07, N 3.33
42	H	4-SCH ₃	H	N(CH ₃) ₂	171- 173	274	C ₁₆ H ₁₉ NOS•HCl Not determined
43	H	3,4-Cl ₂	H	NHCH ₃	162- 164	298, 296	C ₁₅ H ₁₅ Cl ₂ NO•HCl C 54.32, H 4.55, N 4.22: C 54.05, H 4.76, N 4.17
44	4-CN	3,4-Cl ₂	H	NHCH ₃	200- 205	309, 307	C ₁₅ H ₁₂ Cl ₂ N ₂ O•HCl• ½ H ₂ O C 51.75, H 3.91, N 8.05: C 51.82, H 3.80, N 7.83
45	5-SO ₂ - NHCH ₃	3,4-Cl ₂	H	NHCH ₃	202- 204	376, 374	C ₁₅ H ₁₆ Cl ₂ N ₂ O ₃ S•HCl C 43.75, H 4.16, N 6.80: C 43.66, H 3.88, N 6.37
46	4-OCH ₃	3,4-Cl ₂	H	N(CH ₃) ₂	113- 115	328, 326	C ₁₆ H ₁₇ Cl ₂ NO ₂ • C ₄ H ₄ O ₄ C 54.31, H 4.78, N 3.17: C 54.34, H 4.59, N 2.97
47	5-CH ₃	3,4-Cl ₂	H	N(CH ₃) ₂	196- 198	312, 310	C ₁₆ H ₁₇ Cl ₂ N•HCl C 55.43, H 5.23, N 4.04: C 55.28, H 5.12, N 4.00

EXAMPLE 52**(2-FLUORO-6-(P-TOLYLOXY)BENZYL)-DIMETHYLAMINE MALEATE (I, R^{1,2} = CH₃)**

Under N₂, a solution of 0.120 g (0.52 mmol) of 2-fluoro-6-(p-tolyloxy)benzylamine
 5 (from example 3) in 2 mL of CH₃OH was treated with 215 mL (2.86 mmol) of 37% aqueous
 formaldehyde (Aldrich), producing a solid precipitate. Sodium triacetoxyborohydride (0.319 g,

1.43 mmol) was then added, producing some foaming before becoming a clear solution. After stirring at room temperature overnight, H₂O and EtOAc were added, the aqueous layer was further extracted with EtOAc, and the organic layers were combined and washed with H₂O and saturated NaCl. After drying over MgSO₄, the solvent was removed in vacuo to give a
5 light yellow film, 0.110 g.

Mass spectrum (APCI, m/z): 260 (m⁺¹).

¹H-NMR (CDCl₃, 400 MHz): d 7.28 (m, 1H), 7.14 (m, 2H), 6.91 (m, 2H), 6.83 (t, 1H), 6.56 (d, 1H), 4.38 (s, 2H), 2.79 (s, 6H), 2.32 (s, 3H).

The crude amine (84 mg) was dissolved in Et₂O and treated with 38 mg (1 equiv.) of
10 maleic acid in 2 mL of acetone. After stirring at room temperature for 18 hr, the white solid salt was filtered and washed with small amounts of Et₂O and dried under high vacuum to give 0.048 g of the title product, m.p. 147-148 °C.

Elemental analysis for C₁₆H₁₈FNO•C₄H₄O₄ calculated: C, 63.99, H, 5.90, N, 3.73. Found: C, 63.97, H, 5.91, N, 3.67.

15

EXAMPLE 53

4-(3,4-DICHLOROPHOXY)-3-(DIMETHYLAMINOMETHYL)-PHENYLAMINE HYDROCHLORIDE

Under N₂, in a 250 mL Parr apparatus bottle, 0.265 g of 10% Pd on carbon was treated with 30 mL of EtOAc and 0.53 g (1.55 mmol) of [2-(3,4-dichlorophenoxy)-5-nitrobenzyl]-dimethylamine (prepared as in Preparation 1) followed by 2 drops of acetic acid. The mixture was hydrogenated at 40-45 psi of H₂ for 90 min, at which time no starting material was visible by tlc (90:10 CHCl₃:CH₃OH). Saturated NaHCO₃ was added to adjust the pH>7 and the solution was filtered through a pad of d.e., washing the pad with H₂O and EtOAc. The organic layers were combined, washed with H₂O and saturated NaCl, dried over MgSO₄ and
25 concentrated in vacuo to a tan oil, 0.325 g.

Mass spectrum (APCI, m/z): 313, 311.

¹H-NMR (CDCl₃, 400 MHz): d 7.39 (m, 2H), 7.21 (m, 3H), 6.70 (dd, 1H), 4.52 (s, 2H), 2.89 (s, 6H).

The oil was dissolved in Et₂O and treated with 2.1 mL of 1.0 M HCl in Et₂O (Aldrich),
30 stirred at room temperature for 2 hr. and filtered. After drying in vacuo, the title product weighed 0.286 g, m.p. 228 °C.

EXAMPLE 54

N-[4-(3,4-DICHLOROPHOXY)-3-DIMETHYLAMINOMETHYLPHENYL]-ACETAMIDE HYDROCHLORIDE

35 To a suspension of 0.130 g (0.375 mmol) of 4-(3,4-dichlorophenoxy)-3-(dimethylaminomethyl)-phenylamine hydrochloride (from example 53) in 3 mL of toluene at

room temperature, under N₂, was added 110 mL of triethylamine. After 2 hr, 28 mL (0.394 mmol) of acetyl chloride was added and the mixture was stirred another 1 hr before being diluted with EtOAc and saturated aqueous NaHCO₃. The aqueous layer was further extracted with EtOAc and the organic layers were combined, washed with H₂O and saturated NaCl, 5 dried with MgSO₄ and concentrated to a tan oil, 0.116 g.

Mass spectrum (APCI, m/z): 355, 353.

The crude product was dissolved in Et₂O and treated with 330 mL of 1.0 M HCl in Et₂O. After stirring at room temperature, the solids were filtered and washed with small amounts of Et₂O, then dried in vacuo to give the title product, 88 mg, m.p. 199-202 °C.

10 Elemental Analysis calculated for C₁₇H₁₈Cl₂N₂O₂·HCl·½ H₂O: C, 50.64, H, 5.12, N, 6.95. Found: C, 50.51, H, 5.19, N, 6.66.

EXAMPLE 55

2-[2-(3,4-DICHLOROPHOXY)-5-FLUOROPHENYL]-PYRROLIDINE HYDROCHLORIDE

A. 2-(3,4-DICHLOROPHOXY)-5-FLUORO-BENZOIC ACID

15 Under N₂ in a round-bottomed flask fitted with a reflux condenser and magnetic stirrer were placed 6.37 g (19.55 mmol) of cesium carbonate and 3.2 g (19.55 mmol) of 3,4-dichlorophenol (both from Aldrich Chem. Co., Milwaukee, WI) in 60 mL of anhydrous toluene. After stirring the mixture for 5 min., 89 mg (0.24 mmol) of copper (II) trifluoromethansulfonate (copper triflate) and 0.26g (9.78 mmol) of 5-fluoro-2-iodobenzoic acid (prepared according to the 20 method in Collection of Czechoslovakian Chemical Communications, 1975, vol. 40, p728) were added and the mixture was heated to reflux overnight. Progress of the reaction was monitored using thin layer chromatography (tlc), eluting with CHCl₃:CH₃OH:AcOH (9:1:0.5). After allowing the reaction to cool to room temperature, the mixture was diluted with water and EtOAc; the aqueous layer was acidified with 6 N HCl and re-extracted with additional EtOAc. 25 The organic layers were combined, washed with H₂O and saturated NaCl and dried over MgSO₄. Removal of the solvent in vacuo gave a dark brown colored oil, 2.6 g, as a mixture of title product and unreacted 5-fluoro-2-iodobenzoic acid.

Alternatively, a solution of 4.28 g (15 mmol) of 2-(3,4-dichloro-phenoxy)-5-fluorobenzaldehyde (Preparation no. 5) in 25 mL of acetone was cooled to 5-10 °C and 30 treated via syringe with 5.8 mL (15.6 mmol) of 2.67 M Jones reagent *. After 1 hr at this temperature, the reaction was quenched with 8 mL of isopropanol, allowed to warm to 25 °C, and filtered through a pad of d.e. The filtrate was concentrated in vacuo to approximately ¼ volume, diluted with water and extracted several times with CHCl₃. The organic layers were washed with water, then with saturated NaCl and finally dried over MgSO₄ and concentrated 35 to provide 2-(3,4-dichlorophenoxy)-5-fluoro-benzoic acid as a tan solid, 4.19 g. ¹H-nmr (CDCl₃, 400 MHz, δ): 7.78 (dd, 1H), 7.38 (d, 1H), 7.27 (m, 1H), 6.98 (m, 2H), 6.81 (dd, 1H).

*Jones reagent was prepared from 13.4 g of chromium trioxide and 11.5 mL of concentrated H₂SO₄, diluted to a final volume of 50 mL with H₂O.

B. 2-(3,4-DICHLOROPHENOXY)-5-FLUORO-BENZOIC ACID ETHYL ESTER

The preceding mixture in 75 mL of ethanol was treated with 1 mL of H₂SO₄ and heated to 5 reflux for 7 hr, then stirred overnight at room temperature. The solvent was removed in vacuo and the residue was dissolved in EtOAc, was with water, saturated aqueous Na₂CO₃ and then water. After drying with MgSO₄, the solvent was evaporated to give a brown oil, 2.1 g. ¹H-nmr (CDCl₃, 400 MHz, δ): 7.64 (dd, 1H), 7.31 (d, 1H), 7.22 (m, 1H), 7.03 (dd, 1H), 6.92 (s, 1H), 6.72 (dd, 1H), 4.24 (q, 2H), 1.19 (t, 3H).

10 C. 3-[2-(3,4-DICHLOROPHENOXY)-5-FLUOROBENZOYL]-1-VINYL-PYRROLIDIN-2-ONE.

Under N₂, a solution of 12.2 mL (12.2 mmol) of 1.0M lithium bis-(trimethylsilyl)amide in THF (Aldrich Chem. Co.) was stirred and cooled to -30 °C while 781 μL (0.812 g, 7.31 mmol) of 1-vinyl-2-pyrrolidinone (Aldrich Chem. Co.) was added via syringe. After stirring at this 15 temperature for 1 hr, the preceding ethyl ester in 20 mL of THF was added to produce a nearly black solution. This mixture was stirred at room temperature for 72 hr, then diluted with water and EtOAc. The aqueous layer was further extracted with EtOAc and the organic layers were combined, washed with water and saturated NaCl, dried over MgSO₄ and concentrated in vacuo to a tan foam, 2.18 g. This material was used without purification in the following 20 step.

D. 5-[2-(3,4-DICHLOROPHENOXY)-5-FLUOROPHENYL]-2,3-DIHYDRO-1H-PYRROLE

The preceding material was combined with 40 mL of 6N HCl and refluxed for 30 min., producing a gummy precipitate. 1,4-Dioxane (30 mL) was added and the resulting solution 25 was refluxed an additional 30 hr to give a black solution. The reaction was made basic with saturated aqueous K₂CO₃ and extracted three times with EtOAc. The combined organic extracts were washed with water and saturated NaCl, dried with MgSO₄ and treated with activated charcoal (Darco G60). Filtration through d.e., washing the pad well with EtOAc and concentration of the filtrate provided a tan oil, 0.803 g, used without further purification in the 30 next step. Mass spectrum (m/e): 325, 323 (m⁺).

E. 2-[2-(3,4-DICHLOROPHENOXY)-5-FLUOROPHENYL]-PYRROLIDINE HYDRO-CHLORIDE

To 0.300 g (0.93 mmol) of the preceding material in 15 mL of absolute ethanol was added 70 mg (1.86 mmol) of sodium borohydride at room temperature under an N₂ atmosphere 35 (Caution: foaming). After 24 hr, a tlc (CHCl₃:CH₃OH, 95:5) showed a new polar product had formed. Water was added to quench residual sodium borohydride and the mixture was

evaporated to a clear oil which was redissolved in EtOAc and washed with water. The organic layer was further washed with water, saturated NaCl and then dried with MgSO₄. Removal of the solvent in vacuo gave a clear film, 0.202g.

Mass Spectrum (m/e): 328, 326 (m⁺¹).

- 5 ¹H-nmr (CDCl₃, 400 MHz, δ): 7.35 (dd, 1H), 7.32 (d, 1H), 6.96 (d, 1H), 6.87 (m, 2H), 6.73 (dd, 1H), 4.26 (t, 1H), 3.11 (m, 1H), 2.97 (m, 1H), 1.78 (m, 2H), 1.52 (m, 1H).

The free base was dissolved in 5 mL Et₂O and treated with 622 mL of 1.0 M HCl in Et₂O, then stirred for 1.5 hr to produce the title compound hydrochloride salt as pale yellow solids, 165 mg, m.p. 171-173 °C

- 10 Mass Spectrum (m/e): 328, 326 (m⁺¹).

Elemental analysis calculated for C₁₆H₁₄Cl₂FNO•HCl: C, 52.99; H, 4.17; N, 3.86. Found: C, 53.23; H, 4.25; N, 3.89.

EXAMPLE 56

[2-(3,4-DICHLOROPHOXY)-5-FLUOROBENZYL]-METHYLAMINE.

- 15 Under N₂, a mixture of 0.313g (1.0 mmol) of 2-(3,4-dichlorophenoxy)-5-fluoro-N-methylbenzamide in 5.0 mL of anhydrous tetrahydrofuran (THF) was treated via syringe with 4.0 mL (4.0 mmol) of 1.0 M BH₃ in THF (Aldrich Chem. Co.). and the mixture was heated to reflux for a total of 48 hr. The reaction was quenched by the addition of 25 mL of 6N HCl and heating to reflux until the free amine could be detected by tlc (CHCl₃:CH₃OH:TEA, (95:5:1)). The cooled mixture was then diluted with water, basified with K₂CO₃ and extracted with EtOAc. The combined organic layers were washed with water and saturated NaCl, then dried with MgSO₄, filtered and concentrated in vacuo to the free base as a light brown oil, 0.164 g, 54%). This compound was converted to the hydrochloride salt as described previously, m.p. 200-202 °.
- 20

EXAMPLE 57

2-(3,4-DICHLOROPHOXY)-5-FLUORO-BENZYLAMINE

- A flame-dried flask containing N₂ inlet and magnetic stirrer was charged with 3.0 mL of 2.0 M borane methyl sulfide complex in THF (6.0 mmol, Aldrich Chem. Co.), followed by an additional 10 mL of anhydrous THF at room temperature. While stirring, 0.562 g (2.0 mmol) of 2-(3,4-dichlorophenoxy)-5-fluoro-benzonitrile (title compound of Preparation 37) was added slowly via syringe, causing some mild foaming. After the addition, the reaction was heated at reflux for a total of 3 hr, and a tlc (CHCl₃:CH₃OH:conc. NH₄OH, 95:5:1) showed no starting material remaining. With ice bath cooling, the reaction was quenched using 10 mL of 6N HCl, heated to reflux an additional 1 hr to break the boron complex and slowly made basic with saturated aqueous Na₂CO₃. The mixture was diluted with water and EtOAc, the organic layer was combined with a second EtOAc extraction of the aqueous layer and then washed with water and saturated aqueous NaCl. After drying over MgSO₄, the solvent was removed in
- 30
- 35

vacuo to give a yellow tan oil, 0.676 g. The oil was partitioned between Et₂O and 6N HCl, the Et₂O layer was reextracted with 6N HCl and the aqueous layers were combined, made basic with aqueous Na₂CO₃ and reextracted with Et₂O. These latter organic extracts were dried (MgSO₄) and concentrated in vacuo to a tan oil, 0.538 g.

- 5 Mass spectrum (APCI, m/z): 286 (m⁺), 288.


The oil was dissolved in Et₂O and treated with 2.0 mL of 1.0 M HCl in Et₂O. The resulting solids were stirred at room temperature for 2 hr, filtered, washed with Et₂O and dried under vacuum to give the hydrochloride salt of the title product, 0.434 g, m.p. 190-194 °C.

Elemental Analysis calculated for C₁₃H₁₀Cl₂FNO•HCl: C, 48.40, H, 3.43, N, 4.34.

- 10 Found: C, 48.22, H, 3.80, N, 4.28.

CLAIMS

1. A compound of the formula



wherein phenyl ring A and phenyl ring B can each, independently, be replaced by a naphthyl

- 5 group, and wherein when phenyl ring A is replaced by a naphthyl group, the ethereal oxygen of structure I and the carbon to which R³, R⁴ and NR¹R² are attached, are attached to adjacent ring carbon atoms of the naphthyl group and neither of said adjacent ring carbon atoms is also adjacent to a fused ring carbon atom of said naphthyl group;

n and m are, selected, independently, from one, two and three;

- 10 R¹ and R² are selected, independently, from hydrogen, (C₁-C₄)alkyl, (C₂-C₄)alkenyl, and (C₂-C₄)alkynyl, or R¹ and R², together with the nitrogen to which they are attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R¹ and R² are attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, with the proviso that said ring can not contain two adjacent oxygen atoms or two adjacent sulfur atoms, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C₁-C₆)alkyl;
- 15

- 15 R³ and R⁴ are selected, independently, from hydrogen and (C₁-C₄) alkyl optionally substituted with from one to three fluorine atoms, or R³ and R⁴, together with the carbon to which they are attached, form a four to eight membered saturated carbocyclic ring, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C₁-C₆)alkyl;

- 20
- 25 or R² and R³, together with the nitrogen to which R² is attached and the carbon to which R³ is attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R² is attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, with the proviso that said ring can not contain two adjacent oxygen atoms or two adjacent sulfur atoms, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C₁-C₆)alkyl;

each X is selected, independently, from hydrogen, halo (i.e., chloro, fluoro, bromo or iodo), (C₁-C₄)alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₄)alkoxy optionally substituted with from one to three fluorine atoms, cyano, nitro, amino, (C₁-C₄)alkylamino, di-[(C₁-C₄)alkyl]amino, NR⁵(C=O)(C₁-C₄)alkyl, SO₂NR⁵R⁶ and SO_p(C₁-C₆)alkyl,
5 wherein R⁵ and R⁶ are selected, independently, from hydrogen and (C₁-C₆)alkyl, and p is zero, one or two; and

each Y is selected, independently, from hydrogen, (C₁-C₆)alkyl and halo;

with the proviso that: (a) no more than one of NR¹R², CR³R⁴ and R²NCR³ can form a ring; and (b) at least one X must be other than hydrogen when (i) R³ and R⁴ are both
10 hydrogen, (ii) R¹ and R² are selected, independently, from hydrogen and (C₁-C₄)alkyl, and (iii) ring B is mono- or disubstituted with, respectively, one or two halo groups;
or a pharmaceutically acceptable salt thereof.

2. A compound or salt according to claim 1, wherein n is one, X is fluoro, R³ and R⁴ are hydrogen, R¹ is hydrogen, R² is methyl, m is two and Y_m is 3,4-dichloro.

15 3. A compound or salt according to claim 1, wherein m is zero, n is one, R³ and R⁴ are hydrogen, X is chloro, bromo, iodo or methyl, R¹ is hydrogen and R² is methyl.

4. A compound or salt according to claim 1, wherein said compound or salt is selected from the following compounds and their pharmaceutically acceptable salts:

- [2-(3,4-Dichlorophenoxy)-5-fluorobenzyl]-dimethylamine;
20 [2-(3,4-Dichlorophenoxy)-5-fluorobenzyl]-methylamine;
[2-(3,4-Dichlorophenoxy)-5-trifluoromethylbenzyl]-dimethylamine;
N-[4-(3,4-Dichlorophenoxy)-3-dimethylaminomethylphenyl]-acetamide;
{1-[2-(3,4-Dichlorophenoxy)phenyl]-ethyl}-dimethylamine;
[2-(3,4-Dichlorophenoxy)-4-trifluoromethylbenzyl]-dimethylamine;
25 [2-(3,4-Dichlorophenoxy)-4-trifluoromethylbenzyl]-methylamine;
[4-Chloro-2-(3,4-dichlorophenoxy)-benzyl]-methylamine;
{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine;
{1-[2-(3,4-Dichlorophenoxy)phenyl]-ethyl}-methylamine;
{1-[2-(4-Chlorophenoxy)phenyl]ethyl}-methylamine;
30 [2-(3,4-Dichlorophenoxy)-5-methoxybenzyl]-methylamine;
[2-(4-Chlorophenoxy)-5-fluorobenzyl]-methylamine;
{1-[2-(4-Chlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine;
[2-(3,4-Dichlorophenoxy)-5-methylbenzyl]-dimethylamine;
[4-Bromo-2-(3,4-dichlorophenoxy)-benzyl]-methylamine;
35 [5-Bromo-2-(3,4-dichlorophenoxy)-benzyl]-methylamine;
[2-(3,4-Dichlorophenoxy)-4,5-dimethoxybenzyl]-methylamine;

[2-(3,4-Dichlorophenoxy)-4-methoxybenzyl]-dimethylamine;
4-(3,4-Dichlorophenoxy)-3-methylaminomethyl-benzonitrile;
[2-(3,4-Dichlorophenoxy)-4,5-dimethylbenzyl]-methylamine;
3-(3,4-Dichlorophenoxy)-4-methylaminomethyl-benzonitrile;

5 (+)-{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine;
(-)-{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine;
[2-(3,4-Dichlorophenoxy)-5-trifluoromethyl-benzyl]-methylamine;
[2-(3,4-Dichlorophenoxy)-4-methoxybenzyl]-methylamine;
[2-(4-Chloro-3-fluorophenoxy)-5-fluorobenzyl]-methylamine;

10 [2-(3-Chloro-4-fluorophenoxy)-5-fluorobenzyl]-methylamine;
(+/-)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine;
(-)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine;
(+)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine; and
2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-N-methylpyrrolidine;

15 5. A pharmaceutical composition for treating a disorder or condition selected from hypertension, depression (e.g., depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders (involving changes in motility and secretion),

20 negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder (ADHD), chronic paroxysmal hemicrania and headache (associated with vascular disorders) in a mammal, preferably a human, comprising an amount of a compound according to claim 1 that is effective in treating such disorder or condition and

25 a pharmaceutically acceptable carrier.

6. A pharmaceutical composition for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition
5 and a pharmaceutically acceptable carrier.

7. A method for treating a disorder or condition selected from hypertension, depression (e.g., depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia,
10 gastrointestinal tract disorders (involving changes in motility and secretion), negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder (ADHD), chronic paroxysmal hemicrania and headache (associated with vascular disorders) in a mammal, comprising administering to a mammal in
15 need of such treatment an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition.
20
25

8. A method for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound according to
30 claim 1, that is effective in treating such disorder or condition.

9. A pharmaceutical composition for treating a disorder or condition selected from hypertension, depression (e.g., depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode
35 depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and

simple phobias), posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders (involving changes in motility and secretion), negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder (ADHD), chronic paroxysmal hemicrania and headache (associated with vascular disorders) in a mammal, comprising a serotonin, dopamine or norepinephrine reuptake inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, norepinephrine or dopamine in a mammal, comprising serotonin, dopamine or norepinephrine reuptake inhibiting effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

11. A method for treating a disorder or condition selected from hypertension, depression (e.g., depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, sexual dysfunction (e.g., premature ejaculation), eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders (involving changes in motility and secretion), negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention

deficit hyperactivity disorder (ADHD), chronic paroxysmal hemicrania and headache (associated with vascular disorders) in a mammal, preferably a human, comprising administering to a mammal requiring such treatment a serotonin, dopamine or norepinephrine reuptake inhibiting effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

12. A method for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, norepinephrine or dopamine in a mammal, comprising administering to a mammal requiring such treatment a serotonin, dopamine or norepinephrine reuptake inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition for treating a condition or disorder that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, comprising:

- a) a pharmaceutically acceptable carrier;
- 15 b) a compound according to claim 1; and
- c) an NK-1 receptor antagonist or a 5HT_{1D} receptor antagonist, or a pharmaceutically acceptable salt thereof;


wherein the amount of the active compounds (*i.e.*, the compound of formula I and the NK-1 receptor antagonist or 5HT_{1D} receptor antagonist) are such that the combination is effective in treating such disorder or condition.

14. A method for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, comprising administering to a mammal requiring such treatment:

- a) a compound of the formula I, defined above, or a pharmaceutically acceptable salt thereof; and
- b) an NK-1 receptor antagonist or 5HT_{1D} receptor antagonist, or a pharmaceutically acceptable salt thereof;


wherein the amounts of the active compounds (*i.e.*, the compound of formula I and the NK-1 receptor antagonist or 5HT_{1D} receptor antagonist) are such that the combination is effective in treating such disorder or condition.

15. A compound of the formula



wherein Q is -C(=O)H, cyano, -C(=O)OH, or -C(=O)NR¹R² wherein R¹ and R² are selected, independently, from hydrogen and (C₁-C₄)alkyl, or R¹ and R², together with the nitrogen to which they are attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R¹ and R² are attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur.

- 5 16. A compound having the formula



or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PC., IB 00/00108

A. CLASSIFICATION OF SUBJECT MATTER			
IPC 7 C07C217/58 C07C255/37 C07C235/34 A61P25/24 A61P25/28 A61K31/135			
B. FIELDS SEARCHED			
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07C A61K			
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched			
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)			
C. DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
X	DATABASE CSCHEM [Online] Chemical Sources International, Inc. retrieved from STN Database accession no. 11250 XP002135477 * RN = 175136-89-7, 2-AMINOMETHYL-3-CHLORODIPHENYLETHER * abstract ---	1	
A	EP 0 807 621 A (LILLY INDUSTRIES LTD., UK) 19 November 1997 (1997-11-19) example 7 ---	1	
A	EP 0 516 234 A (AKZO N. V., NETH.) 2 December 1992 (1992-12-02) cited in the application the whole document ---	1	
	-/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.	
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed			
T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. & document member of the same patent family			
Date of the actual completion of the international search		Date of mailing of the international search report	
12 April 2000		16. 06. 2000	
Name and mailing address of the ISA		Authorized officer	
European Patent Office, P.B. 5818 Patentstaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Bader, K	

INTERNATIONAL SEARCH REPORTInternational Application No
PCT, IB 00/00108**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 161 529 A (BEREGI LASZLO ET AL) 17 July 1979 (1979-07-17) cited in the application * see the examples * -----	1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 00/00108

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:-
Although claims 7, 8, 11, 12, 14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds/compositions.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See extra sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-14 (in part)

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-14 (in part)

Compounds of formula (I) in claim 1 according to the generic definitions in claim 1, in which ring A and ring B both represent phenyl.

2. Claims: 1-14 (in part)

A compound according to claim 1, where ring A is represented by naphtyl and ring B is represented by phenyl.

3. Claims: 1-14 (in part)

A compound according to claim 1, where ring A is represented by naphthyl and ring B is represented by naphthyl.

4. Claims: 1-14 (in part)

A compound according to claim 1, where ring A is represented by phenyl and ring B is represented by naphthyl.

5. Claim : 15; 16 (in part)

The intermediates of claim 15 and the compound of claim 16 in which ring A is substituted by a fluorine atom in meta position and ring B is substituted by two generic groups in meta and para position which both comprise the structural element -OCH(OH).

6. Claim : 16 (in part)

The compound of claim 16 in which ring B is substituted by a -SCH₃ group in para position.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC., IB 00/00108

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0807621	A 19-11-1997	CA 2204846 A		13-11-1997
		JP 10067723 A		10-03-1998
		US 5863947 A		26-01-1999
<hr/>				
EP 0516234	A 02-12-1992	AT 127777 T		15-09-1995
		AU 650136 B		09-06-1994
		AU 1710492 A		03-12-1992
		CA 2068373 A		30-11-1992
		DE 69204743 D		19-10-1995
		DE 69204743 T		04-04-1996
		DK 516234 T		29-01-1996
		ES 2079783 T		16-01-1996
		FI 922433 A		30-11-1992
		GR 3018357 T		31-03-1996
		IE 67144 B		06-03-1996
		JP 5148197 A		15-06-1993
		NO 178395 B		11-12-1995
		US 5430063 A		04-07-1995
		US 5190965 A		02-03-1993
		ZA 9203283 A		27-01-1993
<hr/>				
US 4161529	A 17-07-1979	GB 1561411 A		20-02-1980
		AT 128978 A		15-07-1980
		AU 3355278 A		30-08-1979
		BE 864312 A		24-08-1978
		CA 1101872 A		26-05-1981
		CH 631162 A		30-07-1982
		DD 134088 A		07-02-1979
		DE 2807623 A		31-08-1978
		ES 467286 A		16-10-1978
		FR 2381753 A		22-09-1978
		GR 63171 A		28-09-1979
		IN 147858 A		19-07-1980
		JP 1026679 C		25-12-1980
		JP 53105475 A		13-09-1978
		JP 55016577 B		02-05-1980
		NL 7802069 A		29-08-1978
		NZ 186552 A		31-08-1979
		OA 5895 A		31-05-1981
		PH 13661 A		26-08-1980
		PT 67698 A, B		01-03-1978
		YU 33278 A		31-10-1982
		ZA 7801100 A		31-01-1979
<hr/>				